



Complex Cases,
Simplified™



Patent Owners' Demonstratives MicroSurgical Technology, Inc. The Regents of the University of California

IPR Nos. 2020-01573, 2020-01711, 2021-00017, 2021-00065, 2021-00066

	01573 ('729)	00017 ('885)	01711 ('155)	00065 ('905)	00066 ('544)
Specification	same				
Claim Elements	ab interno	ab interno	ab interno		ab interno
	dual blade	dual blade	dual blade	knife blades	
	concurrently cutting				
	protruding tip	tip	blunt protruding tip	tip	tip
			blunt top edge		
				protector member (upwardly sloping incline)	foot member (angled platform)
Prior Art	Quintana	Quintana	Quintana	Quintana	Quintana
	Quintana + Lee	Jacobi	Quintana +Lee	Jacobi	Jacobi
	Jacobi		Jacobi		

'729 Patent, -01573
 '885 Patent, -00017
 '155 Patent, -01711

Ex. 1001

US009107729B2

(12) United States Patent
Sorensen et al.

(10) Patent No.: **US 9,107,729 B2**
 (45) Date of Patent: **Aug. 18, 2015**

(54) **DUAL BLADE OPHTHALMOLOGIC SURGERY DEVICE**

(58) **Field of Classification Search**
 CPC A61F 2009/00868; A61F 9/007; A61F 9/00736-9/00763; A61F 9/013-9/0133; A61F 9/00781; A61F 9/0079; A61B 17/320016; A61B 18/1482; A61B 2018/00083; A61B 2018/1497
 USPC 606/107, 161-162, 166-167, 170, 606/184-185; 600/566, 567
 See application file for complete search history.

References Cited

U.S. PATENT DOCUMENTS

3,294,085 A 12/1966 Wallace
 3,882,872 A 5/1975 Douvas et al.
 (Continued)

FOREIGN PATENT DOCUMENTS

EP 0073803 A1 3/1983
 EP 1455698 A1 9/2004
 (Continued)

OTHER PUBLICATIONS


Minncker et al. "Clinical results with the trabectome, a novel surgical device for treatment of open angle glaucoma" trans an ophthalmol soc/ vol. 104 2006.*
 (Continued)

Primary Examiner — Amy R Weisberg
 (74) *Attorney, Agent, or Firm* — Robert D. Buyan; Stout, Uxa & Buyan, LLP

ABSTRACT

Methods and devices for cutting strips of tissue from masses of tissue inside or outside of the bodies of human or animal subjects. The device generally comprises a) an elongate cutting tube that has a distal end and a lumen that opens through an opening in the distal end and b) first and second cutting edges formed on generally opposite edges of the distal end of the cutting tube and separated by a distance D. The device is advanced through tissue to cut a strip of tissue of approximate width W. Width W is approximately equal to distance D.

10 Claims, 3 Drawing Sheets



Petitioner - New World Medical
 Ex. 1001, p. 1 of 10

US009820885B2

(12) United States Patent
Sorensen et al.

(10) Patent No.: **US 9,820,885 B2**
 (45) Date of Patent: **Nov. 21, 2017**

(54) **DUAL BLADE OPHTHALMOLOGIC SURGERY DEVICE**

(58) **Field of Classification Search**
 CPC A61F 9/00781; A61F 9/0079; A61F 9/007; A61F 2009/00868; A61F 9/00736-9/00763; A61F 9/013-9/0133; A61F 9/00781; A61F 9/0079; A61B 17/320016; A61B 18/1482; A61B 2018/00083; A61B 2018/1497
 USPC 606/167, 107, 166, 170, 184, 185; 600/566-567; 30/304-305, 287
 See application file for complete search history.

References Cited

U.S. PATENT DOCUMENTS

421,855 A 2/1890 Burk
 637,463 A 11/1899 Hegarty
 (Continued)

FOREIGN PATENT DOCUMENTS

EP 0973803 A1 3/1983
 EP 1455698 A1 9/2004
 (Continued)

OTHER PUBLICATIONS


U.S. Patent Office Action dated Sep. 29, 2009 in related U.S. Appl. No. 10/560,267, filed May 11, 2006.
 (Continued)

Primary Examiner — Amy R Weisberg
 (74) *Attorney, Agent, or Firm* — Robert D. Buyan; Stout, Uxa & Buyan, LLP

ABSTRACT

A dual blade device and method useable for performing an ab interno procedure within a human eye to remove a strip of trabecular meshwork tissue.

11 Claims, 3 Drawing Sheets



Petitioner - New World Medical
 Ex. 1001, p. 1 of 10

'729 Patent 3:10-17

by a distance D, as shown in the distal end view of FIG. 3B. In the particular example shown in the drawings, the first and second cutting edges 20, 22 are located on opposite lateral sides of the distal end of the cutting tube 14 and a blunt, protruding tip 24 is located on the bottom of the distal end of the cutting tube. Also, a blunt edge 26 is located at the top of the distal end of the cutting tube 14. Thus, only the lateral cutting edges 20, 22 are sharp and intended to cut tissue. The

US 9,107,729 B2

3

the scope of the claims recited in this patent application and any patent(s) issuing therefrom.

One example of a needle cutter device 10 of the present invention is shown in FIGS. 1-4. This needle cutter device 10 generally comprises an elongate cutting tube 14 that has a distal end and a lumen 27 that opens through an opening in the distal end. First and second cutting edges 20, 22 are formed on generally opposite edges of the distal end of the cutting tube 14. These first and second cutting edges 20, 22 are separated by a distance D, as shown in the distal end view of FIG. 3B. In the particular example shown in the drawings, the first and second cutting edges 20, 22 are located on opposite lateral sides of the distal end of the cutting tube 14 and a blunt, protruding tip 24 is located on the bottom of the distal end of the cutting tube. Also, a blunt edge 26 is located at the top of the distal end of the cutting tube 14. Thus, only the lateral cutting edges 20, 22 are sharp and intended to cut tissue. The blunt, protruding tip 24 can, in some applications, be configured and used to facilitate insertion of the device 10 to its intended location and/or the blunt protruding tip 24 may be placed in an anatomical or manual groove or channel (e.g., Schlemm's Canal) of the eye) such that it will then advance through the channel or groove and guide the advancement and positioning of the remainder of the device 10.

One or more bends or curves may optionally be formed in the cutting tube 14 to facilitate its use for its intended purpose. For example, in the embodiment of the device 10 shown in FIG. 2, a single bend 17 of the cutting tube 14 is formed near the distal end of the cutting tube 14. In the embodiment of the device 10 shown in FIG. 6, two separate bends of approximately 90 degrees each are formed at spaced apart locations on the cutting tube 14, thereby giving the cutting tube 14 a generally U shaped configuration. It will be appreciated that any number of bends or curves, in any direction and of any severity may be formed in the cutting tube 14 to facilitate its use in specific procedures or to enable it to be inserted through tortuous anatomical channels of the body. In most cases, the degree of curvature in embodiments where a single bend or curve is formed will be between approximately 30 and approximately 90 degrees and in embodiments where more than one bend or curve are formed in the cutting tube 14 each such bend or curve will typically be between approximately 15 to approximately 90 degrees.

As shown in FIG. 4, when the cutting tube 14 is advanced through tissue, distal end first, the first and second cutting edges 20, 22 will cut a strip ST of tissue having approximate width W, such approximate width W being approximately equal to the distance D between the first and second cutting edges 20, 22. The severed strip ST of tissue will enter the lumen 27 of the cutting tube 14 as the device advances. Negative pressure may be applied to lumen 27 to aspirate the strip ST of tissue and/or fluid and/or other matter through lumen 27.

The device 10 may optionally include a second lumen. Such second lumen may be used for infusion of fluid through the device 10 or for other purposes. In the embodiment shown in FIGS. 1 and 2, the device 10 comprises an outer tube 16 in addition to the cutting tube 14. The cutting tube 14 is of smaller diameter than the outer tube 16 and the cutting tube 14 may extend through the lumen 19 of the outer tube 16 such that a distal portion of the cutting tube 14 extends out of and beyond the distal end of the outer tube 16, as may be seen in FIG. 2. The distal end of the outer tube 16 is tapered and in close approximation with the outer surface of the cutting tube 14. Fluid may be infused through the lumen 19 of the outer tube 16, through the space between the outer surface of the cutting tube 14 and the inner surface of the outer tube 16.

4

Fluid that is infused through the lumen 19 of the outer tube 16 may flow out of one or more apertures 11 formed near the distal end of the outer tube.

In some embodiments, the device 10 may be equipped with severing apparatus for severing (e.g., transversely cutting or transecting) the strip ST of tissue to fully excise or detach the strip ST of tissue from the remaining tissue mass and/or from the body of a human or animal subject. Such severing apparatus may comprise any suitable type of tissue cutter such as a blade, scissor, guillotine, electrode(s), laser, energy emitting tissue cutter, mechanical tissue cutter, etc. FIG. 5 shows an example of an embodiment of the device 10a wherein monopolar or bipolar electrode(s) 40 are located on the distal end of the cutting tube 14. When it is desired to sever the strip ST of tissue, the electrode(s) is/are energized with sufficient energy to sever the strip ST, thereby disconnecting the strip ST from the remaining tissue mass and/or the body of the human or animal subject.

In some embodiments of the device 10, the cutting edges 20, 22 may be heated such that they will cauterize as the cut. As those of skill in the art will appreciate, such heating of the cutting edges 20, 22 may be accomplished by placement of electrode(s) near the cutting edges 20, 22 such that, when the electrode(s) is/are energized, the cutting edges 20, 22 will become heated to a temperature suitable for the desired cauterization function.

The needle cutter device 10 of the present invention may optionally be used as part of a system 12, as shown in FIG. 1. The basic components of the system 12 comprise an aspiration pump module 74 and a source of irrigation fluid 72, mounted on a surgical roller cart 70. Control of the console functions during procedures may be accomplished by an aspiration foot pedal 78 which controls an aspiration pump 74 and variation in the height of the source of irrigation fluid 72 to change the gravity fed pressure or flow rate of irrigation fluid through the device. A pinch valve, or other means, may also be incorporated in the console to control flow of the irrigation fluid to the needle cutter device 10. In embodiments that include apparatus (e.g., electrode(s)) for heating the cutting edges 20, 22 and/or for severing the strip ST of tissue (FIG. 5), the system 12 may additionally comprise an electrical current source, such as an electrosurgical generator 76 and electrosurgical foot pedal 80 which controls the electrosurgical generator to deliver desired amount(s) of energy to the electrode(s) or other electrical elements (e.g., resistance heaters, etc.) on the device 10. As an option, all of the basic control functions of system 12 may be integrated into a single footpedal to facilitate use.

The device 10 may be provided as a pre-sterilized, single-use disposable probe or tip that is attachable to a standard surgical irrigation/aspiration handpiece such as that commercially available as The Rhein I/A Tip System from Rhein Medical, Inc., Tampa, Fla. After the device 10 has been attached to the handpiece, it may be connected to any or all of the electrosurgical generator module 76, aspiration pump module 74 and the source of irrigation fluid 72, as shown. Thus, the device 10 may be fully equipped for irrigation, aspiration, and electrosurgical capabilities, as described herein.

FIGS. 3A-3D show an example of a method for manufacturing the cutting tube 14 from standard tubing (e.g., stainless steel hypodermic tubing). Initially, the distal end of a tube is cut to form the lateral cutting edges 20, 22, the protruding tip 24 and the blunt top edge 26. Thereafter, if it is desired to have one or more bends or curves in the cutting tube 14, angular cut out(s) 30 may be formed in the tube 14, as shown in FIG. 3C.

Pettitioner - New World Medical
Ex. 1001, p. 8 of 10

'729 Patent 3:44-50

As shown in FIG. 4, when the cutting tube 14 is advanced through tissue, distal end first, the first and second cutting edges 20, 22 will cut a strip ST of tissue having approximate width W, such approximate width W being approximately equal to the distance D between the first and second cutting edges 20, 22. The severed strip ST of tissue will enter the lumen 27 of the cutting tube 14 as the device advances.

US 9,107,729 B2

3

the scope of the claims recited in this patent application and any patent(s) issuing therefrom.

One example of a needle cutter device 10 of the present invention is shown in FIGS. 1-4. This needle cutter device 10 generally comprises an elongate cutting tube 14 that has a distal end and a lumen 27 that opens through an opening in the distal end. First and second cutting edges 20, 22 are formed on generally opposite edges of the distal end of the cutting tube 14. These first and second cutting edges 20, 22 are separated by a distance D, as shown in the distal end view of FIG. 3B. In the particular example shown in the drawings, the first and second cutting edges 20, 22 are located on opposite lateral sides of the distal end of the cutting tube 14 and a blunt, protruding tip 24 is located on the bottom of the distal end of the cutting tube. Also, a blunt edge 26 is located at the top of the distal end of the cutting tube 14. Thus, only the lateral cutting edges 20, 22 are sharp and intended to cut tissue. The blunt, protruding tip 24 can, in some applications, be configured and used to facilitate insertion of the device 10 to its intended location and/or the blunt protruding tip 24 may be placed in an anatomical or natural groove or channel (e.g., Schlemm's Canal of the eye) such that it will then advance through the channel or groove and guide the advancement and positioning of the remainder of the device 10.

One or more bends or curves may optionally be formed in the cutting tube 14 to facilitate its use for its intended purpose. For example, in the embodiment of the device 10 shown in FIG. 2, a single bend 17 of approximately 90 degrees is formed near the distal end of the cutting tube 14. In the embodiment of the device 10 shown in FIG. 6, two separate bends of approximately 90 degrees each are formed at spaced apart locations on the cutting tube 14, thereby giving the cutting tube 14 a generally U shaped configuration. It will be appreciated that any number of bends or curves, in any direction and of any severity may be formed in the cutting tube 14 to facilitate its use in specific procedures or to enable it to be inserted through tortuous anatomical channels of the body. In most cases, the degree of curvature in embodiments where a single bend or curve is formed will be between approximately 30 and approximately 90 degrees and in embodiments where more than one bend or curve are formed in the cutting tube 14 such such bend or curve will typically be between approximately 15 to approximately 90 degrees.

As shown in FIG. 4, when the cutting tube 14 is advanced through tissue, distal end first, the first and second cutting edges 20, 22 will cut a strip ST of tissue having approximate width W, such approximate width W being approximately equal to the distance D between the first and second cutting edges 20, 22. The severed strip ST of tissue will enter the lumen 27 of the cutting tube 14 as the device advances. Negative pressure may be applied to lumen 27 to aspirate the strip ST of tissue and/or fluid and/or other matter through lumen 27.

The device 10 may optionally include a second lumen. Such second lumen may be used for infusion of fluid through the device 10 or for other purposes. In the embodiment shown in FIGS. 1 and 2, the device 10 comprises an outer tube 16 in addition to the cutting tube 14. The cutting tube 14 is of smaller diameter than the outer tube 16 and the cutting tube 14 may extend through the lumen 19 of the outer tube 16 such that a distal portion of the cutting tube 14 extends out of and beyond the distal end of the outer tube 16, as may be seen in FIG. 2. The distal end of the outer tube 16 is tapered and in close approximation with the outer surface of the cutting tube 14. Fluid may be infused through the lumen 19 of the outer tube 16, through the space between the outer surface of the cutting tube 14 and the inner surface of the outer tube 16.

4

Fluid that is infused through the lumen 19 of the outer tube 16 may flow out of one or more apertures 11 formed near the distal end of the outer tube.

In some embodiments, the device 10 may be equipped with severing apparatus for severing (e.g., transversely cutting or transecting) the strip ST of tissue to fully excise or detach the strip ST of tissue from the remaining tissue mass and/or from the body of a human or animal subject. Such severing apparatus may comprise any suitable type of tissue cutter such as a blade, scissor, guillotine, electrode(s), laser, energy emitting tissue cutter, mechanical tissue cutter, etc. FIG. 5 shows an example of an embodiment of the device 10a wherein monopolar or bipolar electrode(s) 40 are located on the distal end of the cutting tube 14. When it is desired to sever the strip ST of tissue, the electrode(s) is/are energized with sufficient energy to sever the strip ST, thereby disconnecting the strip ST from the remaining tissue mass and/or the body of the human or animal subject.

In some embodiments of the device 10, the cutting edges 20, 22 may be heated such that they will cauterize as cut. As those of skill in the art will appreciate, such heating of the cutting edges 20, 22 may be accomplished by placement of electrode(s) near the cutting edges 20, 22 such that, when the electrode(s) is/are energized, the cutting edges 20, 22 will become heated to a temperature suitable for the desired cauterization function.

The needle cutter device 10 of the present invention may optionally be used as part of a system 12, as shown in FIG. 1. The basic components of the system 12 comprise an aspiration pump module 74 and a source of irrigation fluid 72, mounted on a surgical roller cart 70. Control of the console functions during procedures may be accomplished by an aspiration foot pedal 78 which controls an aspiration pump 74 and variation in the height of the source of irrigation fluid 72 to change the gravity fed pressure or flow rate of irrigation fluid through the device. A pinch valve, or other means, may also be incorporated in the console to control flow of the irrigation fluid to the needle cutter device 10. In embodiments that include apparatus (e.g., electrode(s)) for heating the cutting edges 20, 22 and/or for severing the strip ST of tissue (FIG. 5), the system 12 may additionally comprise an electrical current source, such as an electrosurgical generator 76 and electrosurgical foot pedal 80 which controls the electrosurgical generator to deliver desired amount(s) of energy to the electrode(s) or other electrical elements (e.g., resistance heater(s), etc.) on the device 10. As an option, all of the basic control functions of system 12 may be integrated into a single footpedal to facilitate use.

The device 10 may be provided as a pre-sterilized, single-use disposable probe or tip that is attachable to a standard surgical irrigation/aspiration handpiece such as that commercially available as The Rhein I/A Tip System from Rhein Medical, Inc., Tampa, Fla. After the device 10 has been attached to the handpiece, it may be connected to any or all of the electrosurgical generator module 76, aspiration pump module 74 and the source of irrigation fluid 72, as shown. Thus, the device 10 may be fully equipped for irrigation, aspiration, and electrosurgical capabilities, as described herein.

FIGS. 3A-3D show an example of a method for manufacturing the cutting tube 14 from standard tubing (e.g., stainless steel hypodermic tubing). Initially, the distal end of a tube is cut to form the internal cutting edges 20, 22, the protruding tip 24 and the blunt top edge 26. Thereafter, if it is desired to have one or more bends or curves in the cutting tube 14, angular cut out(s) 30 may be formed in the tube 14, as shown in FIG. 3C.

Pettitner - New World Medical
Ex. 1001, p. 8 of 10

'729 Patent 4:61-67

US 9,107,729 B2

3
the scope of the claims recited in this patent application and any patent(s) issuing therefrom.

One example of a needle cutter device 10 of the present invention is shown in FIGS. 1-4. This needle cutter device 10 generally comprises an elongate cutting tube 14 that has a distal end and a lumen 27 that opens through an opening in the distal end. First and second cutting edges 20, 22 are formed on generally opposite edges of the distal end of the cutting tube 14. These first and second cutting edges 20, 22 are separated by a distance D, as shown in the distal end view of FIG. 3B. In the particular example shown in the drawings, the first and second cutting edges 20, 22 are located on opposite lateral sides of the distal end of the cutting tube 14 and a blunt, protruding tip 24 is located on the bottom of the distal end of the cutting tube. Also, a blunt edge 26 is located at the top of the distal end of the cutting tube 14. Thus, only the lateral cutting edges 20, 22 are sharp and intended to cut tissue. The

4
fluid that is infused through the lumen 19 of the outer tube 16 may flow out of one or more apertures 11 formed near the distal end of the outer tube.

In some embodiments, the device 10 may be equipped with severing apparatus for severing (e.g., transversely cutting or transecting) the strip ST of tissue to fully excise or detach the strip ST of tissue from the remaining tissue mass and/or from the body of a human or animal subject. Such severing apparatus may comprise any suitable type of tissue cutter such as a blade, scissor, guillotine, electrode(s), laser, energy emitting tissue cutter, mechanical tissue cutter, etc. FIG. 5 shows an example of an embodiment of the device 10a wherein monopolar or bipolar electrode(s) 40 are located on the distal end of the cutting tube 14. When it is desired to sever the strip ST of tissue, the electrode(s) is/are energized with sufficient energy to sever the strip ST, thereby disconnecting the strip ST from the remaining tissue mass and/or the body of the human or animal subject.

In some embodiments of the device 10, the cutting edges 20, 22 may be heated such that they will cauterize as they cut. As those of skill in the art will appreciate, such heating of the cutting edges 20, 22 may be accomplished by placement of electrode(s) near the cutting edges 20, 22 such that, when the electrode(s) is/are energized, the cutting edges 20, 22 will become heated to a temperature suitable for the desired cauterization function.

The needle cutter device 10 of the present invention may optionally be used as part of a system 12, as shown in FIG. 1. The basic components of the system 12 comprise an aspiration pump module 74 and a source of irrigation fluid 72, mounted on a surgical roller cart 70. Control of the console functions during procedures may be accomplished by an aspiration foot pedal 78 which controls an aspiration pump 74 and variation in the height of the source of infusion fluid 72 to change the gravity fed pressure or flow rate of infusion fluid through the device. A pinch valve, or other means, may also be incorporated in the console to control flow of the irrigation fluid to the needle cutter device 10. In embodiments that include apparatus (e.g., electrode(s)) for heating the cutting edges 20, 22 and/or for severing the strip ST of tissue (FIG. 5), the system 12 may additionally comprise an electrical current source, such as an electrosurgical generator 76 and electrosurgical foot pedal 80 which controls the electrosurgical generator to deliver desired amount(s) of energy to the electrode(s) or other electrical elements (e.g., resistance heaters, etc.) on the device 10. As an option, all of the basic control functions of system 12 may be integrated into a single foot pedal to facilitate use.

The device 10 may be provided as a pre-sterilized, single-use disposable probe or tip that is attachable to a standard surgical irrigation/aspiration handpiece such as that commercially available as The Rhein I/A Tip System from Rhein Medical, Inc., Tampa, Fla. After the device 10 has been attached to the handpiece, it may be connected to any or all of the electrosurgical generator module 76, aspiration pump module 74 and the source of irrigation fluid 72, as shown. Thus, the device 10 may be fully equipped for irrigation, aspiration, and electrosurgical capabilities, as described herein.

FIGS. 3A-3D show an example of a method for manufacturing the cutting tube 14 from standard tubing (e.g., stainless steel hypodermic tubing). Initially, the distal end of a tube is cut to form the lateral cutting edges 20, 22, the protruding tip 24 and the blunt top edge 26. Thereafter, if it is desired to have one or more bends or curves in the cutting tube 14, angular cut out(s) 30 may be formed in the tube 14, as shown in FIG. 3C.

Pettitioner - New World Medical
Ex. 1001, p. 8 of 10

FIGS. 3A-3D show an example of a method for manufacturing the cutting tube 14 from standard tubing (e.g., stainless steel hypodermic tubing). Initially, the distal end of a tube is cut to form the lateral cutting edges 20, 22, the protruding tip 24 and the blunt top edge 26. Thereafter, if it is desired to have one or more bends or curves in the cutting tube 14, angular cut out(s) 30 may be formed in the tube 14, as shown in FIG. 3C.

'155 Patent, -01711 Ex. 1001



(12) **United States Patent**
Sorensen et al.

(10) **Patent No.:** US 9,358,155 B2
(45) **Date of Patent:** Jun. 7, 2016

(54) **DUAL BLADE OPHTHALMOLOGIC SURGERY DEVICE**

(58) **Field of Classification Search**

(71) Applicant: **Neomedix Corporation**, Tustin, CA (US)

CPC ... A61F 9/00781; A61F 9/0079; A61F 9/007; A61F 2009/00868; A61F 9/00736-9/00763; A61F 9/013-9/0133; A61B 17/320016; A61B 18/1482; A61B 2018/00085; A61B 2018/1497

(72) Inventors: **John T. Sorensen**, Lake Elsinore, CA (US); **Michael Mittelstein**, Laguna Niguel, CA (US); **Soheila Mirhashemi**, Laguna Niguel, CA (US)

USPC 606/167, 107, 166, 170, 184, 185; 600/566-567; 30/287, 304-305
See application file for complete search history.

(73) Assignee: **NeoMedix Corporation**, Tustin, CA (US)

(56) **References Cited**

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

U.S. PATENT DOCUMENTS
421,855 A * 2/1890 Burk B26B 3/04 30/304
637,463 A * 11/1899 Router B2SD 3/00 30/167
2,130,949 A * 9/1938 Collens A47J 17/04 30/113.3
(Continued)

(21) Appl. No.: **14/789,632**

(22) Filed: **Jul. 1, 2015**

(65) **Prior Publication Data**
US 2015/0297400 A1 Oct. 22, 2015

FOREIGN PATENT DOCUMENTS

Related U.S. Application Data

(60) Continuation of application No. 14/481,754, filed on Sep. 9, 2014, now Pat. No. 9,107,729, which is a division of application No. 13/159,356, filed on Jun. 13, 2011, now abandoned, which is a division of (Continued)

EP 0073803 A1 3/1983
EP 1455698 A1 9/2004
(Continued)
OTHER PUBLICATIONS
US Patent Office Action dated Sep. 29, 2009 in related U.S. Appl. No. 10/560,267, filed May 11, 2006.
(Continued)

(51) **Int. Cl.**
A61B 17/32 (2006.01)
A61F 9/007 (2006.01)
(Continued)


Primary Examiner — Amy R Weisberg
(74) **Attorney, Agent, or Firm** — Robert D. Buyan; Stout, Uxa & Buyan, LLP

(52) **U.S. Cl.**
CPC A61F 9/007 (2013.01); A61B 17/320016 (2013.01); A61B 18/1482 (2013.01); A61F 9/0079 (2013.01); A61F 9/00781 (2013.01);
(Continued)

(57) **ABSTRACT**

A dual blade device comprising an elongate probe having first and lateral second cutting edges and a blunt protruding distal tip, useable for performing an ab interno procedure to remove a strip of trabecular meshwork tissue from a human eye.

7 Claims, 3 Drawing Sheets



Petitioner - New World Medical
Ex. 1001, p. 1 of 10



'155 Patent 6:57-63 (Claim 1)

a blunt top edge that extends transversely from a top end of the first lateral cutting edge to a top end of the second lateral cutting edge and traverses above the area between the first and second lateral cutting edges;

the blunt protruding tip having a transverse width, a top surface, a bottom surface and a terminal end, the transverse width being narrowest at the terminal end;

5
angular cut out 30 into apposition and weld, adhesive or other joining techniques are used to weld or join the apposed edges of the cut outs together, thereby forming the desired bend(s) or curve(s) in the cutting tube 14. Likewise, if it is desired to have one or more bends or curves in the cutting tube 14, the tube 14 may be directly bent to form said curves or bends without the use of angular cut outs(s) 30. It may be appreciated that the use of angular cut outs 30 allows the tube 14 to be

6
A lens device (e.g., Ocular Swan-Jacob Autoclavable Gonioscissors, Model OSIAG, Ocular Instruments Inc., Bellevue, Wash.) may be positioned on the anterior aspect of the eye to enable the physician to clearly visualize the angle of the eye where the segment of trabecular meshwork is to be removed. Under direct visualization, the device 10 is advanced until the distal tip of the cutter tube 14 is positioned adjacent to the trabecular meshwork at the location where the strip ST is to be removed. Thereafter, the protruding tip 24 is advanced through the trabecular meshwork and into Schlemm's Canal.

The device 10 is then advanced along Schlemm's Canal, thereby causing the cutting edges 20, 22 to cut a strip of the trabecular meshwork, thereby creating an opening through which aqueous humor may drain from the anterior chamber of the eye.

After a strip of tissue of the desired length (e.g., about 2-10 mm) has been cut by the lateral cutting edges 20, 22, any optional tissue severing apparatus (e.g., electrode(s) 40 may be used (if present) to transect or sever the strip ST of tissue thereby disconnecting it from the patient's body and allowing it to be aspirated or drawn into or through lumen 27.

Thereafter, the aspiration is stopped, the device 10 is removed from the eye, and the infusion is stopped.

Following completion of the surgery, aqueous humor will drain from the anterior chamber through the opening that was created by removal of the strip of tissue from the trabecular meshwork TM.

Although the invention has been described above with respect to certain embodiments and examples, it is to be appreciated that such embodiments and examples are non-limiting and are not purported to define all embodiments and examples of the invention. Indeed, those of skill in the art will recognize that various modifications may be made to the above-described embodiments and examples without departing from the intended spirit and scope of the invention and it is intended that all such modifications be included within the scope of the following claims.


What is claimed is:

1. A dual blade device useable for performing an ab intern procedure within a human eye to remove a strip of trabecular meshwork tissue, said device comprising:

- a handle configured to be grasped by an operator's hand;
- an elongate probe comprising a shaft that extends from the handle along a longitudinal axis;
- a blunt protruding tip that extends in a lateral direction from a distal end of the shaft to form a bend or curve of approximately 30 degrees to approximately 90 degrees relative to the adjacent longitudinal axis of the shaft;
- first and second lateral cutting edges formed at stationary side-by-side locations on the shaft, said first and second lateral cutting edges facing in the same lateral direction as the blunt protruding tip and being spaced apart such that an area exists between the first and second lateral cutting edges; and
- a blunt top edge that extends transversely from a top end of the first lateral cutting edge to a top end of the second lateral cutting edge and traverses above the area between the first and second lateral cutting edges;
- the blunt protruding tip having a transverse width, a top surface, a bottom surface and a terminal end, the transverse width being narrowest at the terminal end;
- the blunt protruding tip being below the area between the first and second lateral cutting edges and protruding in the lateral direction beyond the first and second lateral cutting edges such that tissue may pass over the top

... facilitate maneuvering of device 10 within the anterior chamber where this alternative approach is used, the device 10 may be disconnected from lumen 27 of the device 10. The device 10 has been inserted into the anterior chamber and the fluid source 72 may be reconnected to lumen 19 of cutter tube 16 such that infusion fluid will flow out of aperture 11. Negative pressure (e.g., via aspiration pump module 74) may then be applied to lumen 27 of the cutter tube 14 so as to aspirate fluid and debris through lumen 27 as shown in FIG. 4. The vertical height of the infusion fluid source 72 may be adjusted to provide sufficient gravity feed of infusion fluid to make up for the volume of fluid or matter being aspirated from the anterior chamber through lumen 27, thereby maintaining the desired pressure of fluid within the anterior chamber during the procedure.

'905 Patent, -00065 Ex. 1001



US010123905B2

(12) **United States Patent**
Mittelstein et al.

(10) **Patent No.:** US 10,123,905 B2
(45) **Date of Patent:** Nov. 13, 2018

(54) **DEVICES USEABLE FOR TREATMENT OF GLAUCOMA AND OTHER SURGICAL PROCEDURES**

(71) Applicant: **NeoMedix Corporation**, Tustin, CA (US)

(72) Inventors: **Michael Mittelstein**, Laguna Niguel, CA (US); **John T. Sorensen**, Lake Elsinore, CA (US); **Sohelia Mirhashemi**, Laguna Niguel, CA (US); **James B Gerg**, Lake Forest, CA (US)

(73) Assignee: **NeoMedix**, Tustin, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 383 days.

(21) Appl. No.: **14923,302**

(22) Filed: **Oct. 26, 2015**

(65) **Prior Publication Data**
US 2016/0106589 A1 Apr. 21, 2016

Related U.S. Application Data

(62) Division of application No. 10/560,266, filed as application No. PCT/US2004/018483 on Jun. 10, 2004.
(Continued)

(51) **Int. Cl.**
A61F 9/007 (2006.01)
A61B 18/14 (2006.01)
(Continued)

(52) **U.S. Cl.**
CPC *A61F 9/00781* (2013.01); *A61B 18/1402* (2013.01); *A61B 18/1482* (2013.01);
(Continued)

(58) **Field of Classification Search**
CPC A61F 9/007; A61F 9/00781; A61F 9/0079; A61B 18/1402; A61B 18/1482;
(Continued)

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,776,238 A 12/1973 Peyman et al.
3,882,872 A 5/1975 Deivas et al.
(Continued)

FOREIGN PATENT DOCUMENTS

EP 0073803 A1 3-1983
EP 1455698 A1 9-2004
(Continued)

OTHER PUBLICATIONS



Anderson, "Trabeculectomy compared to goniotomy for glaucoma in children," *Ophthalmology*, 1983, 90(7), pp. 805-806.
(Continued)

Primary Examiner David Shay
(74) *Attorney, Agent, or Firm* Robert D. Boyan; Stout, Usa & Boyan, L.L.P.

(57) **ABSTRACT**

A device and method for cutting or ablating tissue in a human or veterinary patient includes an elongate probe having a distal end, a tissue cutting or ablating apparatus located adjacent within the distal end, and a tissue protector extending from the distal end. The protector generally has a first side and a second side and the tissue cutting or ablating apparatus is located adjacent to the first side thereof. The distal end is structured to be advanceable into tissue or otherwise placed and positioned within the patient's body such that tissue adjacent to the first side of the protector is cut away or ablated by the tissue cutting or ablating apparatus while tissue that is adjacent to the second side of the protector is not substantially damaged by the tissue cutting or ablating apparatus.


7 Claims, 5 Drawing Sheets

Petitioner - New World Medical
Ex. 1001, p. 1 of 15

'905 Patent 9:2-4

infrared, visible and/or ultraviolet, etc.), **mechanical tissue cutting or ablation apparatus (e.g., knife blade(s), scissor(s), rotating cutter(s), etc.)**, ultrasonic cutting or ablation appa-



'905 Patent 9:9-17

The device 10 further comprises a protector 24 having a first side located adjacent to the cutting or ablating apparatus, and a second side located on a distal-most portion of the device 10. The protector 24 is structured and designed to preventing damage to tissue located near the tissue to be cut. For example, the protector 24 is designed to protect or prevent any substantial damage to surfaces of Schlemm's canal while the device 10 is being utilized to cut portions of the trabecular meshwork during a goniotomy procedure.

9

intensity light, pulsed or non-pulsed laser light, light that is infrared, visible and/or ultraviolet, etc.), mechanical tissue cutting or ablation apparatus (e.g., knife blade(s), scissor(s), rotating cutter(s), etc.), ultrasonic cutting or ablation apparatus (e.g., an ultrasound transmission member that extends through the device to a location adjacent to the first side of the protector and undergoes axial or radial ultrasonic vibration) or others.

The device 10 further comprises a protector 24 having a first side located adjacent to the cutting or ablating apparatus, and a second side located on a distal-most portion of the device 10. The protector 24 is structured and designed to preventing damage to tissue located near the tissue to be cut. For example, the protector 24 is designed to protect or prevent any substantial damage to surfaces of Schlemm's canal while the device 10 is being utilized to cut portions of the trabecular meshwork during a goniotomy procedure.

The device 10 may be structured such that the cutting or ablating apparatus (e.g. the electrosurgical generator 74) is located adjacent to the first side of the protector 24. For example, the protector 24 may be structured such that the cutting or ablating apparatus (e.g. the electrosurgical generator 74) is located adjacent to the first side of the protector 24. For example, the protector 24 may be structured such that the cutting or ablating apparatus (e.g. the electrosurgical generator 74) is located adjacent to the first side of the protector 24.

10

humor from the anterior chamber AC of the eye through Schlemm's Canal and the associated collector channels CC, thereby relieving elevated intraocular pressure.

First, a small incision IN is made in the cornea C at about 3 o'clock in the left eye, or at about 9 o'clock in the right eye. A 1.5 mm slit knife may be used to make this incision IN.

The device 10 is attached to the source of irrigation fluid 72 (e.g., balanced salt solution) such that irrigation fluid will flow through lumen 16 of the outer tube 12 and out of outflow aperture 26. The device 10 is then inserted through the incision IN and into the anterior chamber AC (with irrigation flowing). In some cases, during the insertion of the device 10, the source of irrigation fluid 72 may initially be connected to the device such that the irrigation fluid will flow through the lumen 19 of the distal portion of inner tube 14. In this manner, irrigation fluid will begin to infuse into the anterior chamber AC as soon as the distal tip of the protruding distal portion of inner tube 14 has entered the anterior chamber AC, rather than being delayed until the larger outer tube 12 and aperture 26 have been advanced through the incision IN and into the anterior chamber. By this alternative approach, irrigation fluid may be caused to flow out of the incision IN as the device 10 is being inserted, thereby spreading or opening the incision. Such spreading or opening of the incision IN may facilitate advancement of the larger diameter outer tube 12 through the incision IN. In cases where this alternative approach is used, the source of infusion fluid 72 will be disconnected from lumen 19 after the device has been inserted into the anterior chamber AC and, thereafter, the infusion fluid source 72 will be reconnected to lumen 16 of outer tube 12 such that infusion fluid will flow out of aperture 26. Negative pressure (e.g., via aspiration pump module 74) may then be applied to lumen 19 of the inner tube 14 so as to aspirate fluid and debris through lumen 19. The vertical height of the infusion fluid source 72 may be adjusted to provide sufficient gravity feed of infusion fluid to make up for the volume of fluid or matter being aspirated from the anterior chamber AC through lumen 19, thereby maintaining the desired pressure of fluid within the anterior chamber AC during the procedure.

A lens device (e.g. Ocular Single Mirror Gonioc, Model OSMG, Ocular Instruments, Bellevue, Wash.) may be positioned on the anterior aspect of the eye to enable the physician to clearly visualize the angle A where the segment of trabecular meshwork TM is to be removed. Under such visualization, the device 10 is advanced until the distal tip of the outer tube or inner tube 14 is positioned adjacent to the trabecular meshwork TM at the location where the strip is to be removed. Thereafter, the protector is advanced distally through the trabecular meshwork TM and into Schlemm's Canal SC.

The tissue cutting or ablation apparatus, such as bipolar electrodes 21, 22 or 46, 47, is/are then energized and the device 10 is advanced along Schlemm's Canal, thereby causing the cutting or ablation apparatus, such as bipolar electrodes 21 and 22, to cut or ablate a strip of the trabecular meshwork TM to create opening O, as shown in FIG. 4C.

In the bipolar embodiments of the device 10 shown in FIG. 2 or 5A-5B, discharge of electro-surgical energy via the bipolar electrodes 21, 22 or 46, 47 will remove a full thickness strip of tissue from the trabecular meshwork TM without traumatizing the underlying walls of Schlemm's canal and/or the collector channels, as those structures remain protected from the electro-surgical energy by the insulating protector 24 or 52. The insulated protector 24 or 52 serves two primary purposes: 1) the size and shape of the protector 24 or 52 allows its placement in Schlemm's Canal

11



'905 Patent 14:21-25 (Claim 1)

having a first side, a second side and a tip, wherein the first side of the protector member comprises an incline which slopes upwardly from the tip and wherein the protector member has a width which tapers to its narrowest point at the tip; and

13
insulation may be applied in a liquid form, for example, the insulation may be applied as liquid polyimide, which is then cured.
Once the second electrode 21 is appropriately placed,

US 10,123,905 B2

14
The invention has been described herein with reference to certain examples and embodiments only. No effort has been made to exhaustively describe all possible examples and embodiments of the invention. Indeed, those of skill in the art will appreciate that various additions, deletions, modifications and other changes may be made to the above-described examples and embodiments, without departing from the intended spirit and scope of the invention as recited in the following claims. It is intended that all such additions, deletions, modifications and other changes be included within the scope of the following claims.

What is claimed is:
1. A device that is insertable into the anterior chamber of an eye and useable to form an opening in the trabecular meshwork of that eye, said device comprising:
a) a clongate probe having a longitudinal axis and a distal portion that is insertable into the anterior chamber of an eye;

b) a protector member on a distal end of the distal portion of the probe, the said protector member being oriented in a lateral direction relative to said longitudinal axis and having a first side, a second side and a tip, wherein the first side of the protector member comprises an incline which slopes upwardly from the tip and wherein the protector member has a width which tapers to its narrowest point at the tip; and

c) a plurality of knife blades positioned to cut tissue that passes over the first side of the protector member, wherein the protector member is configured such that, after an insertion of the distal portion of the clongate probe into an anterior chamber of an eye, the protector member is insertable, tip first, through the trabecular meshwork and into Schlemm's Canal, the distal end of the probe being thereafter moveable in the lateral direction thereby causing the protector member to advance through Schlemm's Canal such that trabecular meshwork tissue passes over the incline and a strip of trabecular meshwork tissue becomes cut by said knife blades.

2. A device according to claim 1 wherein the knife blades are operative to cut a strip of tissue having a width from 50 μm to 200 μm, from the trabecular meshwork.

3. A device according to claim 1 further comprising an irrigation lumen.

4. A device according to claim 1 further comprising an aspiration lumen.

5. A device according to claim 1 further comprising an irrigation lumen and an aspiration lumen.

6. A device according to claim 1 wherein the second side of the protector member is configured so as not to damage tissues adjacent thereto as the protector member is advanced through Schlemm's Canal.

7. A device according to claim 1 wherein said knife blades are located a spaced distance apart to cut a strip of tissue the width of which is substantially equal to the distance between the first and second knife blades.

* * * * *

first electrode of the electrode mechanism, is not bent radially inwardly like second leg 22 (FIG. 3C). In addition electrically conductive member 45 may be positioned or disposed generally along a central axis of the inner tube 44 rather than outwardly therefrom such as electrically conductive member 20. The electrically conductive member 45 includes second pole or second electrode 47 of the electrode mechanism.

As shown, electrically conductive member 45 may be held in place by means of bracket portions 49 formed from portions of second leg 46, as shown. The bracket portions 49 are preferably utilized for facilitating positioning of the electrically conductive member 45 during assembly. Adhesive and/or other means may be provided for securing the electrically conductive member 45 in place.

As shown, outer tube 42 may define an irrigation lumen in fluid communication with irrigator port 48. Inner tube 44 may include aspiration/irrigation lumen 50.



'544 Patent, -00066 Ex.1001



(12) **United States Patent**
Baerveldt et al.
 (10) **Patent No.:** US 9,999,544 B2
 (45) **Date of Patent:** *Jun. 19, 2018

(54) **MINIMALLY INVASIVE GLAUCOMA SURGICAL INSTRUMENT AND METHOD**
 (58) **Field of Classification Search**
 CPC A61F 9/00736; A61F 9/00754; A61F 9/00781; A61F 2009/00868; A61F 9/103; (Continued)

(71) Applicant: **The Regents of the University of California**, Oakland, CA (US)
 (72) Inventors: **George Baerveldt**, Monarch Beach, CA (US); **Roy Chuck**, Irvine, CA (US)
 (73) Assignee: **The Regents of the University of California**, Oakland, CA (US)
 (56) **References Cited**
 U.S. PATENT DOCUMENTS
 590,681 A 9/18/97 Harthan
 2,850,007 A 9/19/58 Lingley
 (Continued)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 141 days.
 This patent is subject to a terminal disclaimer.
 FOREIGN PATENT DOCUMENTS
 EP 0073803 B1 7/1985
 EP 0 898 947 A2 3/1999
 (Continued)

(21) Appl. No.: **14/809,043**
 (22) Filed: **Jul. 24, 2015**
 (65) **Prior Publication Data**
 US 2016/0051408 A1 Feb. 25, 2016
Related U.S. Application Data
 (63) Continuation of application No. 13/850,231, filed on Mar. 25, 2013, now Pat. No. 9,226,850, which is a (Continued)

(51) **Int. Cl.**
A61F 9/00 (2006.01)
A61F 9/007 (2006.01)
 (Continued)


(52) **U.S. Cl.**
 CPC **A61F 9/00781** (2013.01); **A61F 9/008** (2013.01); **A61F 9/0079** (2013.01); (Continued)

OTHER PUBLICATIONS
 Aids Excimer laser for Excimer Laser Trabeculotomy. Catalog. Unknown publication date, but predates invention.
 (Continued)

Primary Examiner — Ahmed Farah
 (74) **Attorney, Agent, or Firm** — Kilpatrick Townsend & Stockton LLP

ABSTRACT
 Apparatuses and methods for the treatment of glaucoma are provided. The instrument uses either cauterization, a laser to ablate, sonic or ultrasonic energy to emulsify, or mechanical cutting of a portion of the trabecular meshwork. The instrument may also be provided with irrigation, aspiration, and a footplate. The footplate is used to enter Schlemm's canal, serves as a guide, and also protects Schlemm's canal.

11 Claims, 37 Drawing Sheets



Petitioner - New World Medical
 Ex. 1001, p. 1 of 53



'544 Patent 9:24-27

The probe tip 710 is connected to the main body of the handle 705. The probe tip further comprises a footplate 721, which protects the collector channels, penetrates the trabecular meshwork, and serves as a guide in Schlemm's canal.

9

Aspiration and irrigation may be provided by an aspiration pump 770 and irrigation pump 780. The aspiration pump 770 is connected to a standard vacuum supply line to promote the withdrawal of the aspiration fluid. Aspiration vacuum control may be provided by an aspiration valve. In a preferred embodiment, as shown in FIG. 8, both irrigation and aspiration may be provided by the same lumen 822, alternating the pump as needed. However, the irrigation lumen 922 and aspiration lumen 924 are separate in the embodiment of FIG. 9, providing for simultaneous irrigation and aspiration. Irrigation under pressure flushes blood from the eye and expands the anterior chamber, providing more room for the procedure.

The handle 705 may be made of an electrically insulating polymeric material, configured in a pencil-shape form having a cylindrical body region 702 and a tapered forward region 704. A contoured handle helps to reduce the holding force required and increase proprioceptive sensitivity. Although a pencil-shape configuration is preferred, it is noted that any configuration of the handle 705 which is easily, comfortably and conveniently grasped by the operator will also be suitable and is considered to be within the scope of the present invention.

The probe tip 710 is connected to the main body of the handle 705. The probe tip further comprises a footplate 721, which protects the collector channels, penetrates the trabecular meshwork, and serves as a guide in Schlemm's canal. The canny element 730, located at the distal end of the probe tip 710 may have a variety of configurations.

The tip 710 may be any material, such as titanium, brass, nickel, aluminum, stainless steel, other types of steels, or

US 9,999,544 B2

10

the like. The electrode can also be made of a memory metal, such as nickel titanium. The electrode can also be made of composite construction, whereby different sections are constructed from different materials.

In a preferred embodiment, the probe assembly is bipolar. In a bipolar system, two electrodes of reversed polarity are located on the probe tip, thus eliminating the contact plate for completion of the circuit. Additionally, any number of pairs of electrodes may be provided on the probe tip.

In an alternative embodiment, the probe assembly is monopolar. In a monopolar system, the system comprises a single electrode and a contact plate is attached to the surface of the human body. The contact plate is further connected to the minus terminal of the power source via a lead wire. Voltages of reversed polarity are applied to the electrode and the contact plate.

In a preferred embodiment as shown in FIGS. 10a and 10b, an electrode assembly of a bipolar probe includes one electrode 1020 made from a stainless steel 20 gauge hollow needle and a second electrode 1030 formed as a layer of electrically conductive material (such as silver or nickel) deposited over and adhered to an exterior surface of the needle electrode 1020. A thin electrical insulator 1028 separates the electrodes 1020, 1030, along their lengths to avoid short circuiting.

The electrode 1020 extends along a longitudinal axis 1072 of the footplate 721 (FIG. 7) from a proximal region at which bipolar electrical power is applied to a distal region of the electrode assembly.

In a preferred embodiment, the second electrode 1030 extends over a limited portion of the circumference of the first electrode 1020, rather than entirely around the first electrode. Current flows over a relatively small portion of the circumference and length of the first electrode 1020. This limits the area in the body that receives current, and provides the operator with a high degree of control as to where the current is applied. The second electrode 1030 extends over an arc of approximately one quarter of the circumference of the first electrode 1020. The second electrode 1030 is disposed symmetrically about an axis 1072.

In a preferred embodiment, the first electrode, and thus the footplate 721, has a central passage 1022 that is open at the distal region, providing for irrigation and aspiration. The irrigation and aspiration lumens extend from the distal end of the probe tip 1010, through the probe handle, to the connector, providing for irrigation and aspiration capability.

In an embodiment as shown in FIGS. 11a and 11b, the electrode assembly includes a central or axial electrode 1120 formed by a solid cylindrical metal member, and an elongate hollow outer electrode 1130 formed by a cylindrical metal tube member, which is coaxially positioned around the central electrode 1120. The cylindrical outer surface of electrode 1130 forms the circumferential surface of the probe. The outer electrode 1130 is preferably made of stainless steel or other corrosive resistant, conductive material for strength as well as conductivity. The inner electrode 1120 may be made of copper, but less conductive materials may also be employed. The coaxial relationship and spacing between the electrodes 1120, 1130, as well as their electrical isolation from one another, is provided by a tubular sleeve 1128 of an electrically insulating material between the electrode.

A layer of insulation 1132 may also surround the second electrode 1130. One or more regions of insulating area 1132 may be removed at any suitable location along the axis to expose a region of electrode 1130. Centerization would occur at the exposed region. The circumferential extent of

flow and capacitance coupling with the tissue.
The electrode or other device used to deliver energy can be made of a number of different materials including, but not limited to stainless steel, platinum, other noble metals, and

Petitioner - New World Medical
Ex. 1001, p. 46 of 53

'544 Patent 13:43-45

Goniectomy Cutting Probe. Another preferred embodiment of a goniectomy cutting probe, used to cut and remove trabecular meshwork, is shown in FIG. 18. The probe

US 9,999,544 B2

13

anesthetized the eye. A knife, preferably 20 gauge, is used to make a clear corneal temporal incision. The goniectomy instrument is inserted into the anterior chamber up to the infusion sleeve to maintain the intraocular pressure and deepen the anterior chamber. The surgeon positions the gonio lens, preferably a Schwann-Jacobs lens or a modified Barkan goniotomy lens, on the cornea. The goniectomy probe is advanced to the trabecular meshwork. The sharp end point of the footplate incises the middle one third of the trabecular meshwork, which is known as the pigmented portion of the trabecular meshwork. The footplate 721 (FIG. 7) is further inserted into Schlemm's canal. The cautery element is activated, preferably by a footplate, which may also be used to activate irrigation and aspiration. The current provided to the cautery element heats the tissue. The instru-

14

rotatable drive shaft is inserted into a bore formed in the distal face of the drive member.

The elongate rotatable drive shaft 1944, 2044 passes longitudinally through the probe and terminates, at its distal end, in a cutting head 1945, 2045. A protective tubular sheath may be disposed about the rotatable shaft. The rotatable shaft and/or sheath are axially movable so as to allow the cutting head to be alternately deployed in a) a first non-operative position wherein the cutting head is fully located within the inner bore of the tubular sheath so as to be shielded during insertion and retraction of the instrument or b) a second operative position wherein the cutting head is advanced out of the distal end of the sheath so as to contact and remove the trabecular meshwork. The cutting head 1945, 2045 may be configured such that rotation of the head will create and sustain a forced circulation of fluid within the meshwork. Such forced circulation causes the trabecular meshwork to be pulled or drawn into contact with the rotating, cutting head, without the need for significant axial movement or manipulation of the probe while the cutting head is rotating.

A control pedal may be connected to the motor-drive system to induce actuation/deactuation, and speed control of the rotatable drive cable within the drive cable assembly by the operator. Additional switches or control pedals may be provided for triggering and actuating irrigation and/or aspiration of fluid and/or debris through the probe.

The probe of FIG. 19, shows the probe 1900 having two separate lumens, 1922, 1924, for irrigation and aspiration. The hollow passageway 2022 extending longitudinally through the probe of FIG. 20, containing the rotatable drive shaft, is in fluid communication with an irrigation pump (not shown). By such arrangement, a flow of irrigation fluid may be infused through the tube. A separate lumen 2024 is also provided for aspiration.

The independent processes of irrigation and aspiration may be performed simultaneously with the rotation of the head or while the head is in a non-rotating, stationary mode. It will also be appreciated that the infusion and aspiration pathways may be reversed or interchanged by alternately connecting the aspiration pump to the irrigation tubing and irrigation pump to the aspiration tubing.

In an alternative embodiment, as shown in FIGS. 21-23, the probe cuts tissue in a guillotine fashion. As shown in FIG. 21, the probe 2100 may include an inner sleeve 2144 that moves relative to an outer sleeve 2146. The sleeves are coupled to the handle. The inner sleeve 2144 may be coupled to a vacuum system which pulls tissue into the port 2125 when the inner sleeve 2144 moves away from the port. The inner sleeve 2144 then moves in a reverse direction past the outer port to sever tissue in a guillotine fashion. The vacuum system draws the severed tissue away from the port, so the process may be repeated. The inner sleeve may be connected to a diaphragm and a spring, rigidly attached to the handle. The diaphragm is adjacent to a pneumatic drive chamber that is in fluid communication with a source of pressurized air (not shown). The drive chamber is pressurized, expanding the diaphragm. Expansion of the diaphragm moves the inner sleeve so that the tissue within the port is severed by the sleeve. Alternatively, the inner sleeve 2144 is driven by a motor located within the handle. The inner sleeve 2144 is coupled to the motor by a rotating lever mechanism or wobble plate, inducing an oscillating translational movement of the sleeve in response to a rotation of the output shaft. The motor is preferably an electrical device coupled to an external power source by wires that are attached to a control system at the handle.

ously described. However, rather than cutting the tissue with a knife, the tissue is ablated with the probe. Similarly, in the preferred embodiment, a substantial portion, preferably at least half, of the trabecular meshwork is removed.

Goniectomy Cutting Probe. Another preferred embodiment of a goniectomy cutting probe, used to cut and remove trabecular meshwork, is shown in FIG. 18. The probe comprises a handle 1805 and a probe tip 1810. Preferably, the handle is 20 gauge and the probe tip is approximately 25 gauge. The handle 2405 is sized and configured to fit completely and comfortably within a hand. The handle 2405 may be formed of a variety of materials, including plastics, and may be designed in a variety of shapes. Generally, it will be preferred that a convenient shape for gripping, such as a cylindrical shape, be provided. The probe tip 1810 further comprises a footplate 1820, protecting endothelial cells and collector channels lining the scleral wall of Schlemm's canal. The footplate 1820 also serves as a guide in Schlemm's canal. The sharpened end of the footplate is used to penetrate the trabecular meshwork.

FIGS. 19-20 show sectional views of different embodiments of the internal components and construction of the probe 1800. The probe is configured to define therewithin a hollow inner chamber. A drive member, coupled to a rotatable drive cable within a drive cable assembly, extend into the hollow inner chamber, as shown. A rotatable drive shaft 1944, 2044 is rotatably connected or engaged to the drive member, such that the shaft may be rotatably driven at speeds required for the trabecular meshwork removal. The

Petitioner - New World Medical
Ex. 1001, p. 48 of 53

'544 Patent 13:53-58

cylindrical shape, be provided. The probe tip 1810 further comprises a footplate 1820, protecting endothelial cells and collector channels lining the scleral wall of Schlemm's canal. The footplate 1820 also serves as a guide in Schlemm's canal. The sharpened end of the footplate is used to penetrate the trabecular meshwork.

13
anesthetized the eye. A knife, preferably 20 gauge, is used to make a clear corneal temporal incision. The goniotomy instrument is inserted into the anterior chamber up to the infusion sleeve to maintain the intraocular pressure and deepen the anterior chamber. The surgeon positions the gonio lens, preferably a Schwann-Jacobs lens or a modified Barkan goniotomy lens, on the cornea. The goniotomy probe is advanced to the trabecular meshwork. The sharp

16
preferred that a convenient shape for gripping, such as a cylindrical shape, be provided. The probe tip 1810 further comprises a footplate 1820, protecting endothelial cells and collector channels lining the scleral wall of Schlemm's canal. The footplate 1820 also serves as a guide in Schlemm's canal. The sharpened end of the footplate is used to penetrate the trabecular meshwork.

FIGS. 19-20 show sectional views of different embodiments of the internal components and construction of the probe 1800. The probe is configured to define therewithin a hollow inner chamber. A drive member, coupled to a rotatable drive cable within a drive cable assembly, extend into the hollow inner chamber, as shown. A rotatable drive shaft 1944, 2044 is rotatably connected or engaged to the drive member, such that the shaft may be rotatably driven at speeds required for the trabecular meshwork removal. The

US 9,999,544 B2

14
rotatable drive shaft is inserted into a bore formed in the distal face of the drive member.

The elongate rotatable drive shaft 1944, 2044 passes longitudinally through the probe and terminates, at its distal end, in a cutting head 1945, 2045. A protective tubular sheath may be disposed about the rotatable shaft. The rotatable shaft and/or sheath are axially movable so as to allow the cutting head to be alternately deployed in a) a first non-operative position wherein the cutting head is fully located within the inner bore of the tubular sheath so as to be shielded during insertion and retraction of the instrument or b) a second operative position wherein the cutting head is advanced out of the distal end of the sheath so as to contact and remove the trabecular meshwork. The cutting head 1945, 2045 may be configured such that rotation of the head will create and sustain a forced circulation of fluid within the meshwork. Such forced circulation causes the trabecular meshwork to be pulled or drawn into contact with the rotating, cutting head, without the need for significant axial movement or manipulation of the probe while the cutting head is rotating.

A control pedal may be connected to the motor-drive system to induce actuation/deactuation, and speed control of the rotatable drive cable within the drive cable assembly by the operator. Additional switches or control pedals may be provided for triggering and actuating irrigation and/or aspiration of fluid and/or debris through the probe.


The probe of FIG. 19, shows the probe 1900 having two separate lumens, 1922, 1924, for irrigation and aspiration. The hollow passageway 2022 extending longitudinally through the probe of FIG. 20, containing the rotatable drive shaft, is in fluid communication with an irrigation pump (not shown). By such arrangement, a flow of irrigation fluid may be infused through the tube. A separate lumen 2024 is also provided for aspiration.

The independent processes of irrigation and aspiration may be performed simultaneously with the rotation of the head or while the head is in a non-rotating, stationary mode. It will also be appreciated that the infusion and aspiration pathways may be reversed or interchanged by alternately connecting the aspiration pump to the irrigation tubing and irrigation pump to the aspiration tubing.

In an alternative embodiment, as shown in FIGS. 21-23, the probe cuts tissue in a guillotine fashion. As shown in FIG. 21, the probe 2100 may include an inner sleeve 2144 that moves relative to an outer sleeve 2146. The sleeves are coupled to the handle. The inner sleeve 2144 may be coupled to a vacuum system which pulls tissue into the port 2125 when the inner sleeve 2144 moves away from the port. The inner sleeve 2144 then moves in a reverse direction past the outer port to sever tissue in a guillotine fashion. The vacuum system draws the severed tissue away from the port, so the process may be repeated. The inner sleeve may be connected to a diaphragm and a spring, rigidly attached to the handle. The diaphragm is adjacent to a pneumatic drive chamber that is in fluid communication with a source of pressurized air (not shown). The drive chamber is pressurized, expanding the diaphragm. Expansion of the diaphragm moves the inner sleeve so that the tissue within the port is severed by the sleeve. Alternatively, the inner sleeve 2144 is driven by a motor located within the handle. The inner sleeve 2144 is coupled to the motor by a rotating lever mechanism or wobble plate, inducing an oscillating translational movement of the sleeve in response to a rotation of the output shaft. The motor is preferably an electrical device coupled to an external power source by wires that are attached to a control system at the handle.

Petitioner - New World Medical
Ex. 1001, p. 48 of 53


'544 Patent 23:8-11 (Claim 1)



a foot member which comprises a platform on the distal end of the probe shaft, said platform having a tip, an upper side, a lower side and being set at an angle relative to the longitudinal axis of the probe shaft;



Ex. 1004 (Quintana)



Quintana, p. 3 of 9

GONIOSCOPIC TRABECULOTOMY. FIRST RESULTS

MANUEL QUINTANA
(Barcelona, Spain)

ABSTRACT

We describe a surgical method of goniotrabeculotomy which achieves a section of the trabecular meshwork without damage to the external wall of Schlemm's canal. Complications are minimal. A one year follow-up shows a fall of intraocular pressure in almost all cases. However, this effect is non-lasting and a slow rise in pressure occurs in most cases. Yet, medical therapy, per control than before the operation and usually

We describe a surgical method of goniotrabeculotomy which achieves a section of the trabecular meshwork without damage to the external wall of Schlemm's canal. Complications are minimal. A one year follow-up shows a

INTRODUCTION

Outflow of aqueous through the trabecular meshwork is the pathogenic mechanism in the majority of open-angle glaucomas. Thus, the rational treatment would consist in opening the trabecular meshwork since the last century (11, 12, 13) and many techniques have been described (6, 7), but all the techniques described so far have no in vitro evidence (6, 7) of the effectiveness of

MATERIAL AND METHODS

A technique of trabeculotomy has been devised, which eliminates most of the presumed causes of failure of previous methods. The patient is operated under general anaesthesia; both eyes can be done at the same time. Pupils should be miotic. A coaxial operating microscope is necessary, with magnification of $\times 10$. We favour the Swann lens for angle visualisation. Our trabeculotome is a 0.4×15 mm needle, or an insuline-type needle; we bend the tip $20-30^\circ$ with a needle-holder; a factory-made needle (Morie, France) is even better. The needle is inserted into a syringe filled with "healon". "Modus operandi" is as in classical goniotomy (surgeon in the temporal side of the patient, patient's head rotated away from the surgeon, assistant holding

265

E.L. Greve, W. Leydhecker & C. Raitta (eds.), Second European Glaucoma Symposium, Helsinki 1984.
© 1985, Dr. W. Junk Publishers, Dordrecht. ISBN 978-94-010-8934-0

Petitioner - New World Medical
Ex. 1004, p. 3 of 9

IPR2020-01573 Paper 29 at 1-6, 12-22, 24-39, 42- 45, 48, 54-55; 2020-01711 Paper 17 at 1-7, 20-44, 47-50, 54, 57;
2021-00017 Paper 17 at 1-5, 10-34, 38; 2021-00065 Paper 18 at 1-4, 11-31; 2021-00066, Paper 17 at 1-3, 5, 12-46.

Quintana, p. 3 of 9

GONIOSCOPIC TRABECULOTOMY. FIRST RESULTS

MANUEL QUINTANA
(Barcelona, Spain)

ABSTRACT

We describe a surgical method of goniotrabeculotomy which achieves a section of the trabecular meshwork without damage to the external wall of Schlemm's canal. Complications are minimal. A one year follow-up shows a fall of intraocular pressure in almost all cases. However, this effect is non-permanent in some cases. Yet, medical therapy, before the operation and usually

fication of $\times 10$. We favour the Swann lens for angle visualisation. Our trabeculotome is a 0.4×15 mm needle, or an insuline-type needle; we bend the tip $20-30^\circ$ with a needle-holder; a factory-made needle (Morie, France) is even better. The needle is inserted into a syringe filled with "healon".

through the trabecular meshwork in the majority of open-angle glaucoma cases. The rational treatment of glaucoma by sectioning the trabecular meshwork (11, 12, 13) and many other techniques described so far have not been able to demonstrate the effectiveness of (1, 2, 3, 4, 5, 6, 7) of the effectiveness of

MATERIAL AND METHODS

The technique of trabeculotomy has been devised, which eliminates most of the presumed causes of failure of previous methods. The patient is operated under general anaesthesia; both eyes can be done at the same time. Pupils should be miotic. A coaxial operating microscope is necessary, with magnification of $\times 10$. We favour the Swann lens for angle visualisation. Our trabeculotome is a 0.4×15 mm needle, or an insuline-type needle; we bend the tip $20-30^\circ$ with a needle-holder; a factory-made needle (Morie, France) is even better. The needle is inserted into a syringe filled with "healon". "Modus operandi" is as in classical goniotomy (surgeon in the temporal side of the patient, patient's head rotated away from the surgeon, assistant holding

265

E.L. Greve, W. Leydhecker & C. Raitta (eds.), Second European Glaucoma Symposium, Helsinki 1984.
© 1985, Dr. W. Junk Publishers, Dordrecht. ISBN 978-94-010-8934-0

Petitioner - New World Medical
Ex. 1004, p. 3 of 9

IPR2020-01573 Paper 29 at 1-6, 12-22, 24-39, 42- 45, 48, 54-55; 2020-01711 Paper 17 at 1-7, 20-44, 47-50, 54, 57; 2021-00017 Paper 17 at 1-5, 10-34, 38; 2021-00065 Paper 18 at 1-4, 11-31; 2021-00066, Paper 17 at 1-3, 5, 12-46.

Quintana, p. 4 of 9




Fig. 1. Schematic drawing comparing the tangential approach to the perpendicular approach as in classic goniotomy or goniotrabeculotomy.

the vertical recti). The needle penetrates the anterior chamber at 6 hours (right eye) or 12 hours (left eye) through the *scleral* side of the limbus; this is in order to run parallel to Schlemm's canal. Penetration at 6 or 12 hours allows a *tangential* approach (Fig. 1) to the angle; this avoids the pupillary field and the convexity of the lens. Penetration is carried on under direct control, to avoid the prismatic effect of the goniolens. Once the needle is in

in order to run parallel to Schlemm's canal. Penetration at 6 or 12 hours allows a *tangential* approach (Fig. 1) to the angle; this avoids the pupillary field and the convexity of the lens. Penetration is carried on under direct

inserted, held with the surgeon's left hand, the trabeculotome is progressively introduced into the angle. The tip of the instrument is introduced into the angle slowly, gently and easily from the external wall of the chamber as the needle progresses in the angle. The tip is facing the external wall of the chamber. This is why we bend the tip and we point

the globe clockwise as the needle progresses counter-clockwise. A 100-120° angle can be injected at will at any time if the angle is open. There is usually no chamber loss, but

if this is the case, healon is injected.

Once trabeculotomy is completed, the trabeculotome is withdrawn, taking care of injecting some healon before leaving the anterior chamber (internal "tamponnade"); this avoids any loss of aqueous and the chamber remains full. The goniolens and rectus forceps are also withdrawn. A steroid-antibiotic ointment is applied, as well as a mild mydriatic. The eyes are patched for 24 hours.


266

Petitioner - New World Medical
Ex. 1004, p. 4 of 9

IPR2020-01573 Paper 29 at 1-6, 12-22, 24-39, 42-45, 48, 54-55; 2020-01711 Paper 17 at 1-7, 20-44, 47-50, 54, 57; 2021-00017 Paper 17 at 1-5, 10-34, 38; 2021-00065 Paper 18 at 1-4, 11-31; 2021-00066, Paper 17 at 1-3, 5, 12-46.

Quintana, p. 4 of 9

introduced in the angle. Only the tip of the instrument is introduced into Schlemm's canal, and the TM is stripped slowly, gently and easily from the canal's lumen towards the anterior chamber as the needle progresses in the angle (Fig. 2). Since the convexity of the tip is facing the external wall of the canal, this structure is not damaged. This is why we bend the tip and we point it towards the anterior chamber.



the tangential approach to the perpendicular trabeculotomy.

illustrates the anterior chamber at 6 hours through the scleral side of the limbus; this is Schlemm's canal. Penetration at 6 or 12 hours is carried on under direct vision of the gonioscopes. Once the needle is inserted, held with the surgeon's left hand, a wetting agent between cornea and gonioscopes.

From now on, and with the convexity of the tip towards the surgeon, the trabeculotome is progressively introduced in the angle. Only the tip of the instrument is introduced into Schlemm's canal, and the TM is stripped slowly, gently and easily from the canal's lumen towards the anterior chamber as the needle progresses in the angle (Fig. 2). Since the convexity of the tip is facing the external wall of the canal, this structure is not damaged. This is why we bend the tip and we point it towards the anterior chamber.

As in goniotomy, the assistant will rotate the globe clockwise as the surgeon introduces the trabeculotome counter-clockwise. A 100–120° trabeculotomy can be achieved. Healon can be injected at will at any time if the surgeon wants to deepen the angle. There is usually no chamber loss, but if this is the case, healon is injected.

Once trabeculotomy is completed, the trabeculotome is withdrawn, taking care of injecting some healon before leaving the anterior chamber (internal "tamponnade"); this avoids any loss of aqueous and the chamber remains full. The gonioscopes and rectus forceps are also withdrawn. A steroid-antibiotic ointment is applied, as well as a mild mydriatic. The eyes are patched for 24 hours.

266

Petitioner - New World Medical
Ex. 1004, p. 4 of 9

IPR2020-01573 Paper 29 at 1-6, 12-22, 24-39, 42-45, 48, 54-55; 2020-01711 Paper 17 at 1-7, 20-44, 47-50, 54, 57; 2021-00017 Paper 17 at 1-5, 10-34, 38; 2021-00065 Paper 18 at 1-4, 11-31; 2021-00066, Paper 17 at 1-3, 5, 12-46.

Quintana, p. 5 of 9




Fig. 2. Goniophotography at operation. The tip of the needle stripping the trabecular meshwork.

patients have been operated with this technique, one year (mean). There are 13 eyes with chronic pigmentary glaucoma, 4 disgenetic and 1 steroid-induced in Table 1.

Fig. 2. Goniophotography at operation. The tip of the needle stripping the trabecular meshwork.

steroids and we dilate the pupils (see discussion).

Clinical results

The behaviour of the ocular pressures over one year is represented in Table 1 and Fig. 3. They can be summarized as follows: fall of pressure below 20 mm Hg in almost all cases in the first postoperative weeks, followed by a progressive rise in the second month (mean). From the second month, medical therapy must be reinstated in most cases, although less intensively in regard to the preoperative treatment. At one year, most cases are controlled,

267

Petitioner - New World Medical
Ex. 1004, p. 5 of 9

IPR2020-01573 Paper 29 at 1-6, 12-22, 24-39, 42- 45, 48, 54-55; 2020-01711 Paper 17 at 1-7, 20-44, 47-50, 54, 57; 2021-00017 Paper 17 at 1-5, 10-34, 38; 2021-00065 Paper 18 at 1-4, 11-31; 2021-00066, Paper 17 at 1-3, 5, 12-46.

Quintana, p. 8 of 9

but very few without treatment. Treatment is always weaker than preoperatively.

DISCUSSION

The fall of pressure was predictable and is a clinical proof of the pathogenic mechanism of the TM in open-angle glaucomas. The rise in pressure after a few months indicates that there is some kind of repair in the surgically damaged area. Yet, the trabecular meshwork cells are known not to reproduce; moreover, with this technique the scleral wall of Schlemm's canal is not damaged. But the remaining cells can enlarge, as do the corneal endothelial cells, and this is the subject of our present research; complete repair does not seem to take place in the majority of cases, since in almost all of them the medical control is better than before the operation.

Hyphema is attributed to reflux from the open Schlemm's canal and is always transient.

Iritis with secondary atrophy, similar to the "Urrets syndrome" described after some cases of keratoplasty, is attributed to the liberation of prostaglandins by the damaged trabecular cells. Avoiding postoperative miosis (since the angle is open) and therapy with topical steroids and antiprostaglandins systemically or topically avoids iritis; this complication occurred in some of our first cases, but no more after we instituted the above-mentioned postoperative care.

In conclusion, our results show that goniotrabeculotomy, although highly successful in the first postoperative month, is in the end a partially successful procedure. Further studies are necessary to disclose the "in vivo" behaviour of the sectioned trabecular meshwork.

REFERENCES

In conclusion, our results show that goniotrabeculotomy, although highly successful in the first postoperative month, is in the end a partially successful procedure. Further studies are necessary to disclose the "in vivo" behaviour of the sectioned trabecular meshwork.

IPR2020-01573 Paper 29 at 1-6, 12-22, 24-39, 42- 45, 48, 54-55; 2020-01711 Paper 17 at 1-7, 20-44, 47-50, 54, 57; 2021-00017 Paper 17 at 1-5, 10-34, 38; 2021-00065 Paper 18 at 1-4, 11-31; 2021-00066, Paper 17 at 1-3, 5, 12-46.



Ex. 1005 (Johnstone)

MICROSURGERY OF SCHLEMM'S CANAL AND THE HUMAN AQUEOUS OUTFLOW SYSTEM

MURRAY A. JOHNSTONE, M.D., AND W. MORTON GRANT, M.D.
Boston, Massachusetts

One basis for some of the present approaches to microsurgery of Schlemm's canal is the finding by Grant¹⁻³ that approximately 75% of the resistance of the aqueous outflow system could be eliminated in perfused enucleated human eyes by providing an opening from the anterior chamber into Schlemm's canal by internal trabeculotomy with a cystotome, and that in open-angle glaucomatous eyes, abnormal resistance could be eliminated in the same way. Much earlier, Barkan^{4,5} showed that open-angle glaucoma could be relieved in adults by an internal trabeculotomy with a goniotomy knife. The effect of the Barkan trabeculotomy procedure appears generally not to have been long lasting. The cystotome laboratory procedure has not been readily adaptable to clinical use, but recently Bietti and Quaranta⁶ have reported clinical successes by internal trabeculotomy with another type of cutting instrument.

Other procedures have been devised and applied clinically with the aim of reducing resistance to aqueous outflow by surgery on Schlemm's canal, in particular ab externo trabeculotomy procedures, but their effects have not been evaluated in the same experimental manner as those of internal cystotome trabeculotomy.

The present study was carried out to compare in postmortem enucleated human eyes the changes induced in the structure and function of the trabecular meshwork and Schlemm's canal aqueous outflow system by

internal cystotome trabeculotomy, by ab externo probing of Schlemm's canal with nylon and metal probes, and by causing the probes to rupture from the canal into the anterior chamber as in current clinical practice.

PROCEDURES AND METHODS

Quantitative aqueous perfusion—We made measurements before and after experimental dissections as follows. We stored enucleated normal eyes obtained at autopsy at 4°C in a moist environment until 30 minutes prior to perfusion, which was started 4 to 48 hours post mortem. After removal from refrigeration, we placed the eyes in a silicone rubber mold that enveloped the posterior segment to the equator. We covered the anterior segment with absorbent paper saturated in perfusion fluid. An opening 5 mm in diameter was trephined in the center of the cornea to give access to the anterior chamber and the inner angle. Except in one special group of eyes, we regularly performed a radial iridotomy through the trephine opening to prevent artificial deepening of the chamber. For quantitative aqueous perfusion, we used Bárány's⁷ constant pressure technique, with a commercial, sterile filtered, phosphate-buffered balanced salt solution containing glucose. We infused the solution into the anterior chamber through a stainless steel fitting (previously described), which sealed the opening in the cornea. We generally measured steady state flow while maintaining intraocular pressure at 15 mm Hg, but in certain instances at 5, 30, or 50 mm Hg. The measurements made before each experimental procedure required approximately ten minutes of perfusion to attain what appeared to be a steady state. After manipulation or dissection, we carried out similar perfusion and monitored flow rate for 120 minutes. If the same eye underwent a sec-

ond experimental procedure, perfusion measurement sul group of eyes was perfused for the same length of experimental, omitting the dissection procedures.

Microscopic morphologic examination, tissue fixed with 4% glutaraldehyde, and stained them with 1% osmium tetroxide, dehydrated in ethyl alcohol, cleared in cedar oil, and stained them with 1% toluidine blue. For light microscopy, we stained them with 1% toluidine blue. For scanning electron microscopy, we was fixed for 24 to 48 hours containing equal parts of 1% osmium tetroxide and 4% glutaraldehyde in 0.1M phosphate buffer (pH 7.4) and rinsed in distilled water, cleared in cedar oil, and stained them with 1% toluidine blue. The frozen tissue was coated for three hours under vacuum with 10 nm of gold and 40% palladium. A scanning electron microscope of the quality generally prepared for examination of fine detail is of value in demonstrating the morphologic features in control and experimental gross alterations result from dissection procedures.

Dissections and surgical procedures—Internal cystotome trabeculotomy was performed in 180 degrees of the angle in the same manner as by Tinsnes and Grant.⁸ Through the 5-mm corneal trephine, direct visualization was obtained with a microscope at 25 to 40X magnification. After making a cystotome with the goniotomy knife at right angles to the shaft, we cut from within the angle through the trabecular meshwork, Schlemm's canal, and passed a cannula circumferentially, with

Reprint requests to W. Morton Grant, M.D., Howe Laboratory of Ophthalmology, 243 Charles St., Boston, MA 02114.

906

JULY 76, NO. 6 MIC

second experimental procedure, perfusion measurement sul group of eyes was perfused for the same length of experimental, omitting the dissection procedures.

Microscopic morphologic examination, tissue fixed with 4% glutaraldehyde, and stained them with 1% osmium tetroxide, dehydrated in ethyl alcohol, cleared in cedar oil, and stained them with 1% toluidine blue. For light microscopy, we stained them with 1% toluidine blue. For scanning electron microscopy, we was fixed for 24 to 48 hours containing equal parts of 1% osmium tetroxide and 4% glutaraldehyde in 0.1M phosphate buffer (pH 7.4) and rinsed in distilled water, cleared in cedar oil, and stained them with 1% toluidine blue. The frozen tissue was coated for three hours under vacuum with 10 nm of gold and 40% palladium. A scanning electron microscope of the quality generally prepared for examination of fine detail is of value in demonstrating the morphologic features in control and experimental gross alterations result from dissection procedures.

Dissections and surgical procedures—Internal cystotome trabeculotomy was performed in 180 degrees of the angle in the same manner as by Tinsnes and Grant.⁸ Through the 5-mm corneal trephine, direct visualization was obtained with a microscope at 25 to 40X magnification. After making a cystotome with the goniotomy knife at right angles to the shaft, we cut from within the angle through the trabecular meshwork, Schlemm's canal, and passed a cannula circumferentially, with

Reprint requests to W. Morton Grant, M.D., Howe Laboratory of Ophthalmology, 243 Charles St., Boston, MA 02114.

Reprint requests to W. Morton Grant, M.D., Howe Laboratory of Ophthalmology, 243 Charles St., Boston, MA 02114.

Reprint requests to W. Morton Grant, M.D., Howe Laboratory of Ophthalmology, 243 Charles St., Boston, MA 02114.


Reprint requests to W. Morton Grant, M.D., Howe Laboratory of Ophthalmology, 243 Charles St., Boston, MA 02114.

Reprint requests to W. Morton Grant, M.D., Howe Laboratory of Ophthalmology, 243 Charles St., Boston, MA 02114.

Reprint requests to W. Morton Grant, M.D., Howe Laboratory of Ophthalmology, 243 Charles St., Boston, MA 02114.

Johnstone, p. 1 of 12

pare in postmortem enucleated human eyes




IPR2020-01573 Paper 29 at 37, 45, 55; 2020-01711 Paper 17 at 41-42, 50; 2021-00017 Paper 17 at 31.



Johnstone, p. 1 of 12

internal cystotome trabeculotomy, by ab externo probing of Schlemm's canal with nylon




IPR2020-01573 Paper 29 at 37, 45, 55; 2020-01711 Paper 17 at 41-42, 50; 2021-00017 Paper 17 at 31.



Johnstone, p. 2 of 12


...oving a cystotome with the point oriented
...right angles to the shaft. We inserted the



IPR2020-01573 Paper 29 at 37, 45, 55; 2020-01711 Paper 17 at 41-42, 50; 2021-00017 Paper 17 at 31.

Johnstone, p. 2 of 12

Usually the cystotome pushed a strip of meshwork ahead of itself in the manner of a plow.




IPR2020-01573 Paper 29 at 37, 45, 55; 2020-01711 Paper 17 at 41-42, 50; 2021-00017 Paper 17 at 31.



Johnstone, p. 5 of 12


work in place. The residual material was rather ragged and what was exposed of the external wall of the canal had an irregular pattern.



IPR2020-01573 Paper 29 at 37, 45, 55; 2020-01711 Paper 17 at 41-42, 50; 2021-00017 Paper 17 at 31.

Johnstone, p. 11 of 12

These experiments have provided some surprises and have caused us to reconsider some of our concepts of the workings of antiglaucoma microsurgical procedures on Schlemm's canal. While we again obtained a



IPR2020-01573 Paper 29 at 37, 45, 55; 2020-01711 Paper 17 at 41-42, 50; 2021-00017 Paper 17 at 31.



Ex. 1006 (Lee)

United States Patent [19] [11] **Patent Number:** 4,900,300
Lee [45] **Date of Patent:** Feb. 13, 1990

[54] **SURGICAL INSTRUMENT** 4,689,040 8/1987 Thompson 604/22
 [76] **Inventor:** David A. Lee, 2868 Nicada Dr., #48, Los Angeles, Calif. 90077 FOREIGN PATENT DOCUMENTS
 2450597 11/1980 France 128/757

[21] **Appl. No.:** 315,190
 [22] **Filed:** Feb. 24, 1989 *Primary Examiner—C. Fred Rosenbaum*
Assistant Examiner—Kathleen A. Daley
Attorney, Agent, or Firm—David Silverstein

Related U.S. Application Data
 [63] **Continuation of Ser. No. 70,325, Jul. 6, 1987, abandoned.**
 [51] **Int. Cl.⁴** A61B 17/20
 [52] **U.S. Cl.** 604/22; 606/162; 606/166
 [58] **Field of Search** 604/22, 27, 28; 128/304, 305, 321, 757-758

References Cited
U.S. PATENT DOCUMENTS
 3,542,031 11/1970 Taylor 128/304
 4,011,869 3/1977 Seiler, Jr. 604/22
 4,043,322 8/1977 Robinson 604/22
 4,210,146 7/1980 Banko 128/305
 4,220,155 9/1980 Kimberling et al. 128/305
 4,377,629 3/1986 Martinez 604/22
 4,655,743 4/1987 Hyde 604/22


ABSTRACT
 [57] This invention relates to the design and application of a goniotomy instrument for the purpose of diagnostically and therapeutically removing tissue from the anterior chamber angle of the eye and for retrieving this tissue for further examination. The surgical instrument of this invention comprises in combination: a hollow, tapered shaft having a cutting edge at one end as an integral part thereof; a retractable stylet, contained within the hollow interior of the tapered shaft; and an irrigation port running along the outside of the tapered shaft. This instrument is useful for excising tissue to relieve an obstruction blocking the outflow of aqueous humor from the eye as well as for providing specimens of the excised tissue for histopathological examination.

24 Claims, 1 Drawing Sheet

Petitioner - New World Medical
 Ex. 1006, p. 1 of 11

Lee, p. 4 of 11


The forward end of shaft 10 comprises a parabolic, bowl-like cavity 12 having a sharpened rim which creates a single, more or less U-shaped cutting edge 14 integral with the sides of shaft 10. The cutting edge is



IPR2020-01573 Paper 29 at 3-4, 38-44; 2020-01711 Paper 17 at 3-4, 44-50; 2021-00017 Paper 17 at 31, 41; 2021-00065 Paper 18 at 3, 18, 36, 38; 2021-00066, Paper 17 at 4, 25-26, 37, 47-48.

Lee, p. 5 of 11

FIG. 3. FIG. 4 shows the generally parabolic shape of cutting edge 14, including the softly rounded distal end 15. FIG. 4 also clearly shows aperture 16 in the bottom



IPR2020-01573 Paper 29 at 3-4, 38-44; 2020-01711 Paper 17 at 3-4, 44-50; 2021-00017 Paper 17 at 31, 41; 2021-00065 Paper 18 at 3, 18, 36, 38; 2021-00066, Paper 17 at 4, 25-26, 37, 47-48.

Lee, p. 5 of 11

(6) The cutting edge 14 is used to excise the angle tissue 40 for approximately one-third of the angle circumference. The excised tissue will be guided toward and through aperture 16 in cavity 12 (see FIG. 3) as cutting edge 14 is advanced. This will help to hold the excised tissue in place during removal. The paracentesis entry site is used as a piv-



IPR2020-01573 Paper 29 at 3-4, 38-44; 2020-01711 Paper 17 at 3-4, 44-50; 2021-00017 Paper 17 at 31, 41; 2021-00065 Paper 18 at 3, 18, 36, 38; 2021-00066, Paper 17 at 4, 25-26, 37, 47-48.

Ex. 1007 (Jacobi 1997)



Jacobi 1997, p. 2 of 6

due to glaucoma absolutum. The aim of the surgical procedure was to abrade rather than incise uveal meshwork; this novel method, therefore, is termed goniocurettage. A descrip-



IPR2020-01573 Paper 29 at 4-6, 45-55; 2020-01711 Paper 17 at 4-6, 50-60; 2021-00017 Paper 17 at 3-5, 31-43; 2021-00065 Paper 18 at 3-4, 31-38; 2021-00066, Paper 17 at 4-5, 37, 39-48.

Jacobi 1997, p. 2 of 6

was designed. The 'gonioscraper' consists of a small handle and a slightly convex-shaped arm for intraocular use and very much resembles a cyclodialysis spatula. However, the tip of the instrument is shaped as a tiny bowl with 300 µm diameter and with its edges sharpened (Fig 1). In order to abrade clockwise and anticlockwise the scoop is angulated vertically at 90 degrees to the left and right, respectively.



Figure 1 The tip of the 'gonioscraper'. The bowl is 300 µm in diameter with its edges sharpened.

(trabeculopuncture) removes little tissue and allows filling in and scarring to occur with subsequent closure of the trabecular opening.^{11,12} The present study was carried out to introduce a new approach in glaucoma surgery aiming to scrape pathologically altered trabecular meshwork off the scleral sulcus in six patients suffering from uncontrolled IOP due to glaucoma absolutum. The aim of the surgical procedure was to abrade rather than incise usual meshwork; this novel method, therefore, is termed gonioscrapeg. A description of instrumentation, surgical technique, and preliminary clinical results are given.

Materials and methods

INSTRUMENTATION AND SURGICAL TECHNIQUE
In order to shell the trabecular meshwork out of its scleral sulcus a new surgical instrument was designed. The 'gonioscraper' consists of a small handle and a slightly convex-shaped arm for intraocular use and very much resembles a cyclodialysis spatula. However, the tip of the instrument is shaped as a tiny bowl with 300 µm diameter and with its edges sharpened (Fig 1). In order to abrade clockwise and anticlockwise the scoop is angulated vertically at 90 degrees to the left and right, respectively.

The experimental part of the surgical procedure was carried out on six human eye bank globes, classified unsuitable for keratoplasty. Death had occurred no more than 12 hours

before surgery. Gonioablation was performed under direct visualisation of the anterior chamber angle with an operating microscope and a surgical gonioscopy lens. Following injection of viscoelastic, the 'gonioscraper' was inserted into the anterior chamber through a clear corneal incision at the temporal limbus and directed against the trabecular meshwork at the opposite side. In order to peel off trabecular meshwork the 'scraper' was lightly passed over 2-3 clock hours to either side at the nasal circumference of the anterior chamber angle in sweeping movements (Fig 2). Great care was taken to selectively pare usual meshwork and not to traumatise adjacent intraocular structures, such as the corneal endothelium or the base of the iris. Gonioscopically, strings of trabecular tissue could be observed intraoperatively to be removed by gonioscrapeg, leaving a 'denuded' grey-white scleral sulcus. At the end of surgery the viscoelastic along with abraded trabecular debris were removed by means of an irrigation-aspiration probe.

HISTOLOGICAL PREPARATION

Following surgery three eye banking eyes were processed for scanning electron microscopy as follows: within 5 minutes after treatment, the eyes were immersed in a fixative of 2% glutaraldehyde and 2% paraformaldehyde in 0.1 M phosphate buffer at a pH of 7.4. After 2 hours, the eyes were rinsed in phosphate buffer, and the treated area was dissected out. Specimens for scanning electron microscopy were post-fixed with 1% osmium tetroxide in 0.1 M phosphate buffer at a pH of 7.4. After 2 hours in osmium tetroxide, the scanning specimens were dehydrated in graded alcohols, critical point dried in carbon dioxide, and sputter coated with gold. The specimens were then examined with the scanning electron microscope. Those samples designated for light microscopy were fixed in a 10% formalin solution. After 2 hours dissected samples were dehydrated, embedded in paraffin, sectioned by a microtome, and stained with haematoxylin and eosin for light microscopy.

PATIENTS

Six patients were included in this study all suffering from medically uncontrolled IOP, terminal optic nerve atrophy, and no light perception consequent on chronic open angle glaucoma. Exclusion criteria were: reduced (≥20/40) or threatened vision in the unoperated eye, a history of uveitis, anterior segment media opacity, ocular trauma, and neovascular or angle closure glaucoma. Preoperative evaluation included measurement of visual acuity, quantitative visual field testing if possible, measurement of IOP, gonioscopy, anterior and posterior segment slit-lamp biomicroscopy, indirect ophthalmoscopy of the retina, and ultrasonography when required. Informed consent was obtained from all the patients, following the tenets of the Declaration of Helsinki, after they had been fully informed about the experimental nature of the procedure. Surgery was performed in the above manner using retrobulbar anaesthesia. Treatment in the immediate preoperative period



With the aid of an operating microscope and under gonioscopic control an anterior chamber angle is performed. Following ablation an irregularly shaped, grey-white scleral band (Fig 2) is seen. The 'denuded' grey-white scleral sulcus (black arrow).

Ex. 1007, p. 2 of 6

the opposite side. In order to peel off trabecular meshwork the 'scraper' was lightly passed over 2–3 clock hours to either side at the nasal circumference of the anterior chamber angle in sweeping movements (Fig 2). Great care was

Technique of gonioscraetage, a potential treatment for advanced chronic open angle glaucoma 303

before surgery. Gonioabration was performed under direct visualisation of the anterior chamber angle with an operating microscope and a surgical gonioscopy lens. Following injection of viscoelastic, the 'gonioscraper' was inserted into the anterior chamber through a clear corneal incision at the temporal limbus and directed against the trabecular meshwork at the opposite side. In order to peel off trabecular meshwork the 'scraper' was lightly passed over 2–3 clock hours to either side at the nasal circumference of the anterior chamber angle in sweeping movements (Fig 2). Great care was taken to selectively pare uveal meshwork and not to traumatise adjacent intraocular structures, such as the corneal endothelium or the base of the iris. Gonioscopically, strings of trabecular tissue could be observed intraoperatively to be removed by gonioscraetage, leaving a 'denuded' grey-white scleral sulcus. At the end of surgery the viscoelastic along with abraded trabecular debris were removed by means of an irrigation-aspiration probe.

HISTOLOGICAL PREPARATION
Following surgery three eyes banking eyes were processed for scanning electron microscopy as follows: within 5 minutes after treatment, the eyes were immersed in a fixative of 2% glutaraldehyde and 2% paraformaldehyde in 0.1 M phosphate buffer at a pH of 7.4. After 2 hours, the eyes were rinsed in phosphate buffer, and the treated area was dissected out. Specimens for scanning electron microscopy were post-fixed with 1% osmium tetroxide in 0.1 M phosphate buffer at a pH of 7.4. After 2 hours in osmium tetroxide, the scanning specimens were dehydrated in graded alcohols, critical point dried in carbon dioxide, and sputter coated with gold. The specimens were then examined with the scanning electron microscope. Those samples designated for light microscopy were fixed in a 10% formalin solution. After 2 hours dissected samples were dehydrated, embedded in paraffin, sectioned by a microkeratome, and stained with haematoxylin and eosin for light microscopy.

PATIENTS
Six patients were included in this study all suffering from medically uncontrolled IOP, terminal optic nerve atrophy, and no light perception consequent on chronic open angle glaucoma. Exclusion criteria were: reduced ($\geq 20/40$) or threatened vision in the unoperated eye, a history of uveitis, anterior segment media opacity, ocular trauma, and neovascular or angle closure glaucoma. Preoperative evaluation included measurement of visual acuity, quantitative visual field testing if possible, measurement of IOP, gonioscopy, anterior and posterior segment slit-lamp biomicroscopy, indirect ophthalmoscopy of the retina, and ultrasonography when required. Informed consent was obtained from all the patients, following the tenets of the Declaration of Helsinki, after they had been fully informed about the experimental nature of the procedure. Surgery was performed in the above manner using retrobulbar anaesthesia. Treatment in the immediate preoperative period

Death had occurred no more than 12 hours





Figure 2 With the aid of an operating microscope and under gonioscopic control an internal gonioscraetage is performed. Following ablation an irregular pattern of a glaucoma scleral band corresponding to the 'denuded' grey-white scleral sulcus can be seen (black arrows).

Pestboner - New World Medical
Ex. 1007, p. 2 of 6

IPR2020-01573 Paper 29 at 4-6, 45-55; 2020-01711 Paper 17 at 4-6, 50-60; 2021-00017 Paper 17 at 3-5, 31-43; 2021-00065 Paper 18 at 3-4, 31-38; 2021-00066, Paper 17 at 4-5, 37, 39-48.

Jacobi 1997, p. 2 of 6

base of the iris. Gonioscopically, strings of trabecular tissue could be observed intraoperatively to be removed by gonioscurettage, leaving a 'denuded' grey-white scleral sulcus. At the end of surgery the viscoelastic along with abraded trabecular debris were removed by means of an irrigation-aspiration probe.



IPR2020-01573 Paper 29 at 4-6, 45-55; 2020-01711 Paper 17 at 4-6, 50-60; 2021-00017 Paper 17 at 3-5, 31-43; 2021-00065 Paper 18 at 3-4, 31-38; 2021-00066, Paper 17 at 4-5, 37, 39-48.

Jacobi 1997, p. 3 of 6


in place. Gonioscopically, ragged strings of trabecular tissue could be observed intraoperatively to be removed by gonioscurettage, leaving an irregular pattern of a glistening white band corresponding to the 'denuded' grey-white scleral sulcus as exposed by histology. From



IPR2020-01573 Paper 29 at 4-6, 45-55; 2020-01711 Paper 17 at 4-6, 50-60; 2021-00017 Paper 17 at 3-5, 31-43; 2021-00065 Paper 18 at 3-4, 31-38; 2021-00066, Paper 17 at 4-5, 37, 39-48.

Jacobi 1997, p. 3 of 6


3A and B) it was evident that in addition to peeling and disruption of the trabecular meshwork the gonioscraper caused damage to septa and endothelium of the external wall of Schlemm's canal, and disruption along the posterior wall of the canal. Flaps of uveal



IPR2020-01573 Paper 29 at 4-6, 45-55; 2020-01711 Paper 17 at 4-6, 50-60; 2021-00017 Paper 17 at 3-5, 31-43; 2021-00065 Paper 18 at 3-4, 31-38; 2021-00066, Paper 17 at 4-5, 37, 39-48.

Jacobi 1997, p. 5 of 6

imum resistance to aqueous outflow. In an attempt to avoid early reclosure by secondary fibroproliferation of the remaining uveal meshwork gonioscurettage removes tissue rather than incising or disrupting the uveal meshwork. In



IPR2020-01573 Paper 29 at 4-6, 45-55; 2020-01711 Paper 17 at 4-6, 50-60; 2021-00017 Paper 17 at 3-5, 31-43; 2021-00065 Paper 18 at 3-4, 31-38; 2021-00066, Paper 17 at 4-5, 37, 39-48.

DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
Patent Owner Ex. 2034



Jacobi 1997, p. 5 of 6

Microscopic examination of sections of the angles of treated eye bank eyes confirmed that this new technique produced a deep furrow within the trabecular meshwork, completely removing the inner wall of Schlemm's canal. It commonly disrupted intracanalicular septa and damage to the external wall of the Schlemm's canal was also recognisable. Thus,

however, they observed rather large wound surfaces, possibly facilitating subsequent fibroproliferation and scarring. Thus they came to the conclusion that the observed increase in resistance to aqueous outflow following trabeculotomy is caused by a secondary repair process of the endothelial-trabecular meshwork closing the sites of earlier trabeculotomy.

In this study we describe a new technique in glaucoma microsurgery aimed at dealing directly with the pathoanatomical site of maximum resistance to aqueous outflow. In an attempt to avoid early reclosure by secondary fibroproliferation of the remaining uveal meshwork gonioscurettage removes tissue rather than incising or disrupting the uveal meshwork. In order to do so we designed the 'gonioscraper', a novel microsurgical instrument for transconjunctival use. Despite the obvious difference in surgical instrumentation the procedure itself, to a certain extent, is comparable with the classic technique of goniotomy. Clear visualisation of the chamber angle structures by gonioscopy and a deep and stable anterior chamber are prerequisites for successful surgical treatment. The intended mechanism of action of gonioscurettage is to remove pathologically altered trabecular meshwork and to open a route for aqueous humour to egress either into Schlemm's canal or, in the case of damage of the canal's external wall, to ooze out through microslittings within the posterior scleral wall.

Microscopic examination of sections of the angles of treated eye bank eyes confirmed that this new technique produced a deep furrow within the trabecular meshwork, completely removing the inner wall of Schlemm's canal. In commonly disrupted intracanalicular septa and damage to the external wall of the Schlemm's canal was also recognisable. Thus, the increase in outflow may not be attributable entirely to the elimination of resistance to flow through the trabecular meshwork and inner wall of Schlemm's canal, but also involve a splitting of sclera posteriorly to Schlemm's canal. This ab interno approach may be an advantageous procedure because the conjunctiva remains undisturbed and, if required, a fistulating procedure can be easily performed at a later point.

A clinical trial evaluating the efficacy of gonioscurettage as an antiglaucoma microsurgical procedure in primary open angle glaucoma is currently being carried out. So far, preliminary data from a small group of treated eyes are already available. All six patients experienced an absolute decrease in IOP (mean 22.7 mm Hg, 56% from baseline), but IOP in one patient remained significantly greater than 20 mm Hg. Intraoperatively, the surgical procedure of this phisic patient proved to be more difficult, since extra care had to be taken not to damage the crystalline lens. Surgery was complicated postoperatively by a hyphema from sustained bleeding of the ciliary arteries. Iris major. Five days postoperatively, the hyphema almost cleared without further surgical intervention. Intraocular inflammation was not observed postoperatively in the remaining two eyes. Complications relating to postopera-

tive bulbar hypotony or reduced anterior chamber depth did not evolve. Inadvertent cyclodialysis as a mechanism of pressure reduction was ruled out by means of high frequency ultrasound biomicroscopy in all four cases.

However, the limited number of treated eyes and maximum follow up of only 12 months restrict clinical interpretation. At this point gonioscurettage has to be regarded as an experimental procedure aiming to relieve trabecular outflow resistance. Longer term follow up and a greater number of patients are warranted before this procedure is applicable to eyes that would do well with conventional surgery.

1 Fluorouracil Filtering Surgery Study Group. Three-year follow-up of the Fluorouracil Filtering Surgery Study. *Am J Ophthalmol* 1993;115:82-92.

2 Kawanishi K, Nishimura A, Yamamoto T, Hibber S, Kitayama Y. Anterior chamber reaction after iridectomy and trabeculectomy. *Ophthalmology* 1991;98:317-21.

3 Palmer SS. Mitomycin as adjunct chemotherapy with trabeculectomy. *Ophthalmology* 1991;98:317-21.

4 Jay L, Murray SB. Early trabeculectomy versus conventional management in primary open angle glaucoma. *Br J Ophthalmol* 1988;72:68-72.

5 Berlin MS, Yoo FH, Ahn BHS. The role of laser sclerostomy in glaucoma surgery. *Surv Ocul* Ophthalmol 1999;44:100-10.

6 Labin MA, Dobrowolski MJ. Laser filtration surgery. *Ophthalmol Clin N Am* 1982;2:57-59.

7 Marshall J. Lasers in ophthalmology: the basic principles. *Opt* 1982 (Suppl):8-12.

8 Collier SA, Hill SA, Barrett G, Andrews JL, Burns MW. Infrared laser sclerostomy. *Invest Ophthalmol Vis Sci* 1991;32:1863-7.

9 Freeman GA, Baidar RM, Khorobda B. Current ablation in glaucoma using an infrared CO₂ and erbium:YAG laser on ocular structures. *Ophthalmology* 1989;96:1160-70.

10 Hill SA, Barrett G, Collier SA, Bradford M, Price GA, Burns MW. Laser trabeculectomy. *Lasers Surg Med* 1991;13:34-42.

11 Tawara A, Iwama H. Developmental immaturity of the trabecular meshwork in juvenile glaucoma. *Am J Ophthalmol* 1984;98:82-97.

12 Elias GH. The etiology, symptomatology, and treatment of juvenile glaucoma. *Am J Ophthalmol* 1948;31:183-96.

13 McPherson SD Jr. Early CO₂ laserotomy versus trabeculectomy in developmental glaucoma. *Am J Ophthalmol* 1982;94:627-30.

14 Ripstein DL, Melamed S, Palumbo CA, Sander RP, Freedman DM. Late trabeculectomy in open angle glaucoma. *Ophthalmology* 1982;90:317-7.

15 Terakawa H, Ina A, Okamoto M, Terakawa H, Okudera A, Kurai J, Takemachi A, et al. Surgical effects of trabeculectomy in the presence of high eyes with primary open angle glaucoma and pseudotumor syndrome. *Arch Ophthalmol* 1993;111:167-80.

16 Schwinn G, Grehn F, Ohlert D. Characterization combined with trabeculectomy. *Acta Ophthalmol Scand* 1992;208:144-52.

17 Neerovf AG. Role of bloodside of the Schlemm's canal in pathogenesis in primary open angle glaucoma. *Am J Ophthalmol* 1970;69:618.

18 Neerovf AJ, Bannanov TR. Study on morphology and function of drainage area of the eye of man. *Acta Ophthalmol* 1972;50:317-41.

19 Neerovf AJ, Bannanov TR. Trabeculectomy and Schlemm's canal in the early stage of primary open angle glaucoma. *Am J Ophthalmol* 1978;86:82-92.

20 Segura K. Electron microscopic changes of the trabecular layer in primary open angle glaucoma. *Acta Ophthalmol* 1978;57:273-7.

21 Shabo AL, Forns TS, Gustafsson D. Postmortem formation of giant endothelial vesicles in Schlemm's canal of glaucoma. *Am J Ophthalmol* 1975;79:886-901.

22 Melamed S, Palumbo CA, Ripstein DL. Combined procedure with laser trabeculectomy in myopia. *Am J Ophthalmol* 1982;94:118-23.

23 Ina A, Terakawa H, Okamoto M, Ripstein DL, Terakawa H, Okudera A, Kurai J, Takemachi A, et al. Intraoperative and postoperative changes in trabeculectomy in myopia. *Nippon Ganka Gakkaishi* 1994;98:1-11.

24 Grant WM. Further studies on facility of flow through the trabecular meshwork. *Arch Ophthalmol* 1956;57:53-53.

25 Grant WM. Experimental aqueous perfusion in macaques. *Invest Ocul* Ophthalmol 1969;8:783-97.

26 Grant WM. Laboratory research. Microsurgery of the human choroid (retrospect). *Invest Ocul* Ophthalmol 1972;11:386-402.

27 Driessens WJ, Adelman DC. Primary acetabular glaucoma (congenital glaucoma). *Surv Ophthalmol* 1983;28:1-19.

28 Adelman DC. Trabeculectomy compared to the glaucoma in children. *Ophthalmology* 1983;90:805-9.

IPR2020-01573 Paper 29 at 4-6, 45-55; 2020-01711 Paper 17 at 4-6, 50-60; 2021-00017 Paper 17 at 3-5, 31-43; 2021-00065 Paper 18 at 3-4, 31-38; 2021-00066, Paper 17 at 4-5, 37, 39-48.



Ex. 1013 (Jacobi 2000)

ARTICLE

Perspectives in trabecular surgery

PHILIPP C. JACOBI, THOMAS S. DIETLEIN, GÜNTER K. KRIEGLSTEIN

Abstract

The aim of trabecular surgery is to selectively combat the diseased structure central to the pathogenesis of chronic open-angle glaucoma, thereby reducing potential hazards during and after conventional filtering procedures. This overview considers new techniques in *ab interno* trabecular surgery. Special emphasis is placed on the description of each novel technique, its instrumentation, presumed mechanism of action and clinical results. Trabecular aspiration is evaluated as a method of clearing intertrabecular spaces of extracellular debris in pseudoexfoliation glaucoma with or without simultaneous cataract surgery or gonioscurettage, while laser trabecular ablation is discussed for the treatment of absolute glaucomas. Where corneal haze has formed visualisation of the anterior chamber angle structures and trabecular surgery is performed with the aid of a microscope. Although the results are very promising it should be understood that some of these procedures are still in the experimental phase and are undergoing careful clinical evaluation, leaving plenty of room for refinements and further developments.

Key words Gonioscurettage, Microendoscopy, Trabecular aspiration, Trabecular photolablation

Enormous progress has been made in understanding the complexity of the underlying causes of chronic open-angle glaucoma. However, indisputable concepts for effective treatment are still rare. To date, conventional filtering surgery remains the mainstay of surgical therapy in the management of glaucoma not controlled by medication.¹ Unfortunately, treatments involving full-thickness filtration are scarcely selective since healthy structures not primarily involved in the disease process are subject to surgical intervention. The application of adjunctive antimetabolites for inhibition of undesired episcleral fibroblastic proliferation dramatically increased the success rates for filtering procedures, but had the disadvantage of exacerbating serious side-effects, such as flat anterior chambers, prolonged post-operative hypotony and late endophthalmitis from infected filtering blebs.^{2,3}

Microsurgery on Schlemm's canal and the human aqueous outflow system for controlling intraocular pressure (IOP) in chronic open-angle glaucoma has been evolving over the past few decades. Theoretical considerations indicate that production of approximately 10 to 15 fistulae, each 10 µm in diameter, between the anterior chamber and Schlemm's canal should restore normal outflow facility in open-angle glaucoma.⁴ The basis for most of the current approaches to microsurgery of Schlemm's canal is the finding by Grant⁵ that the largest proportion of resistance to outflow is located within the trabecular meshwork, namely the cribriform layer, and can be eliminated by incising the trabecular meshwork and entering Schlemm's canal. If one agrees that the site of the pathological resistance to aqueous humour outflow is this tissue, its partial removal, taking the utmost possible care not to damage the surrounding chamber angle structures, could be a new alternative in antiglaucomatous surgery. This sort of selective non-penetrating trabecular surgery would be equivalent to internal filtration surgery without transcleral drainage of aqueous humour into the subconjunctival space, and would thereby reduce the incidence of post-operative complications typically associated with filtering procedures.

This review discusses different *ab interno* trabecular microsurgical techniques that are designed to facilitate outflow along its natural pathway. Each new technique is described in detail, newly developed instrumentation is discussed, and the presumed mechanisms of action are outlined. However, the reader must understand that none of these new microsurgical procedures threatens to replace conventional filtering approaches, since they are still in the experimental phase and under careful clinical evaluation, and there is plenty of room left for further refinements and developments. We hope this article will give impetus to the search for alternative strategies in antiglaucomatous surgery, and focus attention more closely on the diseased target structure in chronic open-angle glaucoma: the trabecular meshwork.

P.C. Jacobi
T.S. Dietlein
G.K. Kriegstein
University Eye Hospital
University of Cologne
Cologne, Germany

Philipp C. Jacobi, MD (E)
Department of
Ophthalmology
University of Cologne
Joseph-Stiehmstrasse 9
D-50931 Cologne, Germany
Tel: +49 221 478 4345
Fax: +49 221 478 4347

Bye (2000) 14, 519-530 © 2000 Royal College of Ophthalmologists

519
Pebbloner - New World Media
Ex. 1013, p. 1 of 12


Jacobi 2000, p. 2 of 12

The underlying concept of gonioscurettage is to remove rather than incise or disrupt pathologically altered trabecular meshwork and to open a route for aqueous humour to egress either into Schlemm's canal or, where the external wall of the canal is damaged, to ooze out through microsplittings in the posterior scleral wall.⁶ The


Gonioscurettage

The underlying concept of gonioscurettage is to remove rather than incise or disrupt pathologically altered trabecular meshwork and to open a route for aqueous humour to egress either into Schlemm's canal or, where the external wall of the canal is damaged, to ooze out through microsplittings in the posterior scleral wall.⁶ The procedure is conceptually similar to goniotomy, except that trabecular tissue is scraped away from the scleral sulcus using an instrument similar to a microchalcidion curette (Fig. 1). The gonioscraper consists of a small handle and a slightly convex arm for intraocular use and closely resembles a cyclodialysis spatula. However, the tip of the instrument is shaped like a miniature bowl, 300 µm in diameter, with sharpened edges. To abrade clockwise and counter-clockwise, the scoop is vertically angled at 90° to either side.

Gonioscurettage is usually performed under direct visualisation of the anterior chamber angle through an operating microscope and a surgical gonioscopy lens (Fig. 2). Following injection of viscoelastic, the gonioscraper is inserted into the anterior chamber through a clear corneal incision and directed against the trabecular meshwork on the opposite side. The scraper is lightly passed over 2 to 3 clock-hours to either side of the nasal circumference of the chamber angle. Great care is taken while peeling off the uveal meshwork not to



(a)



(b)

Fig. 1. (a) The tip of the 'gonioscraper'. The external diameter of the bowl is 300 µm and its edges are sharpened. (b) The intraocular arm of the gonioscraper is convex to avoid inadvertent damage to the iris-lens diaphragm.




Fig. 2. Ab interno gonioscurettage is performed with the aid of an operating microscope under gonioscopic observation.

traumatise adjacent intraocular structures, such as the corneal endothelium or the base of the iris. Intraoperatively, ragged strings of trabecular tissue can be seen to be removed by goniosablation, leaving an irregular pattern of a glistening white band corresponding to the denuded grey-white scleral sulcus (Fig. 3). At the end of the procedure, viscoelastic along with abraded trabecular debris is removed by means of irrigation-aspiration.

Morphological analysis of the treatment zones in human donor eyes clearly indicated the potential efficacy of gonioscurettage for completely removing the trabecular meshwork.⁷ From light microscopy of histological sections it is evident that, in addition to the peeling of the trabecular meshwork, gonioscurettage also causes damage to intracanalicular septa and the endothelium of the external wall of Schlemm's canal, and in some instances a disruption along the posterior wall of Schlemm's canal. Flaps of uveal tissue, capable of returning to their predissection position, were not observed in the specimens. Scanning electron microscopy shows that the trabecular meshwork is pulled away from its attachments, leaving ragged structures of Schlemm's canal within the scleral sulcus exposing bare sclera (Fig. 4).




Fig. 3. After goniosablation, an irregular pattern of a glistening white band corresponding to the 'denuded' grey-white scleral sulcus appears (black arrows).

520


Pettitioner - New World Medical
Ex. 1013, p. 2 of 12

IPR2020-01573 Paper 29 at 46, 51, 55; 2020-01711 Paper 17 at 51; 2021-00017 Paper 17 at 35; 2021-00065 Paper 18 at 32; 2021-00066, Paper 17 at 40-42.

DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
Patent Owner Ex. 2034

Jacobi 2000, p. 2 of 12

curette (Fig. 1). The gonioscraper consists of a small handle and a slightly convex arm for intraocular use and closely resembles a cyclodialysis spatula. However, the tip of the instrument is shaped like a miniature bowl, 300 μm in diameter, with sharpened edges. To abrade clockwise and counter-clockwise, the scoop is vertically angled at 90° to either side.



IPR2020-01573 Paper 29 at 46, 51, 55; 2020-01711 Paper 17 at 51; 2021-00017 Paper 17 at 35; 2021-00065 Paper 18 at 32; 2021-00066, Paper 17 at 40-42.

Jacobi 2000, p. 2 of 12

bowl is 300 μm and its edges are sharpened. (b) The intraocular arm of

Goniocurettage

The underlying concept of goniocurettage is to remove rather than incise or disrupt pathologically altered trabecular meshwork and to open a route for aqueous humour to egress either into Schlemm's canal or, where the external wall of the canal is damaged, to ooze out through microsplittings in the posterior scleral wall.⁶ The procedure is conceptually similar to goniotomy, except that trabecular tissue is scraped away from the scleral sulcus using an instrument similar to a microchalcidion curette (Fig. 1). The goniocurette consists of a small handle and a slightly convex arm for intraocular use and closely resembles a cyclodialysis spatula. However, the tip of the instrument is shaped like a miniature bowl, 300 μm in diameter, with sharpened edges. To abrade clockwise and counter-clockwise, the scoop is vertically angled at 90° to either side.

Goniocurettage is usually performed under direct visualisation of the anterior chamber angle through an operating microscope and a surgical gonioscopy lens (Fig. 2). Following injection of viscoelastic, the goniocurette is inserted into the anterior chamber through a clear corneal incision and directed against the trabecular meshwork on the opposite side. The scraper is lightly passed over 2 to 3 clock-hours to either side of the nasal circumference of the chamber angle. Great care is taken while peeling off the uveal meshwork not to






Fig. 2. Ab interno goniocurettage is performed with the aid of an operating microscope under gonioscopic observation.

traumatise adjacent intraocular structures, such as the corneal endothelium or the base of the iris. Intraoperatively, ragged strings of trabecular tissue can be seen to be removed by goniobrasion, leaving an irregular pattern of a glistening white band corresponding to the denuded grey-white scleral sulcus (Fig. 3). At the end of the procedure, viscoelastic along with abraded trabecular debris is removed by means of irrigation-aspiration.

Morphological analysis of the treatment zones in human donor eyes clearly indicated the potential efficacy of goniocurettage for completely removing the trabecular meshwork.⁶ From light microscopy of histological sections it is evident that, in addition to the peeling of the trabecular meshwork, goniocurettage also causes damage to intracanalicular septa and the endothelium of the external wall of Schlemm's canal, and in some instances a disruption along the posterior wall of Schlemm's canal. Flaps of uveal tissue, capable of returning to their predissection position, were not observed in the specimens. Scanning electron microscopy shows that the trabecular meshwork is pulled away from its attachments, leaving ragged structures of Schlemm's canal within the scleral sulcus exposing bare sclera (Fig. 4).



(a)



(b)

Fig. 1. (a) The tip of the 'goniocurette'. The external diameter of the bowl is 300 μm and its edges are sharpened. (b) The intraocular arm of the goniocurette is convex to avoid inadvertent damage to the iris-lens diaphragm.



Fig. 3. After goniobrasion, an irregular pattern of a glistening white band corresponding to the 'denuded' grey-white sulcus sclerae appears (black arrows).

520

Pettitioner - New World Medical
Ex. 1013, p. 2 of 12

IPR2020-01573 Paper 29 at 46, 51, 55; 2020-01711 Paper 17 at 51; 2021-00017 Paper 17 at 35; 2021-00065 Paper 18 at 32; 2021-00066, Paper 17 at 40-42.

Jacobi 2000, p. 2 of 12

Intraoperatively, ragged strings of trabecular tissue can be seen to be removed by gonioabration, leaving an irregular pattern of a glistening white band corresponding to the denuded grey-white scleral sulcus (Fig. 3). At the end of the procedure, viscoelastic along with abraded trabecular debris is removed by means of irrigation-aspiration.

Goniotripsy

The underlying concept of goniotripsy is to remove rather than incise or disrupt pathologically altered trabecular meshwork and to open a route for aqueous humour to egress either into Schlemm's canal or, where the external wall of the canal is damaged, to ooze out through microsplittings in the posterior scleral wall.⁶ The procedure is conceptually similar to goniotomy, except that trabecular tissue is scraped away from the scleral





Fig. 2. Ab interno goniotripsy is performed with the aid of an operating microscope under gonioscopic observation.

ar to a microchalcidion consists of a small for intraocular use and spatula. However, the like a miniature bowl, med edges. To abrade the scoop is vertically

direct against the scraper is either side of the angle. Great care is meshwork not to



(b)

Fig. 1. (a) The tip of the 'gonioscraper'. The external diameter of the bowl is 300 µm and its edges are sharpened. (b) The intracanalicular arm of the gonioscraper is convex to avoid inadvertent damage to the iris-lens diaphragm.

traumatise adjacent intraocular structures, such as the corneal endothelium or the base of the iris. Intraoperatively, ragged strings of trabecular tissue can be seen to be removed by gonioabration, leaving an irregular pattern of a glistening white band corresponding to the denuded grey-white scleral sulcus (Fig. 3). At the end of the procedure, viscoelastic along with abraded trabecular debris is removed by means of irrigation-aspiration.

Morphological analysis of the treatment zones in human donor eyes clearly indicated the potential efficacy of goniotripsy for completely removing the trabecular meshwork.⁷ From light microscopy of histological sections it is evident that, in addition to the peeling of the trabecular meshwork, goniotripsy also causes damage to intracanalicular septa and the endothelium of the external wall of Schlemm's canal, and in some instances a disruption along the posterior wall of Schlemm's canal. Flaps of uveal tissue, capable of returning to their predissection position, were not observed in the specimens. Scanning electron microscopy shows that the trabecular meshwork is pulled away from its attachments, leaving ragged structures of Schlemm's canal within the scleral sulcus exposing bare sclera (Fig. 4).




Fig. 3. After gonioabration, an irregular pattern of a glistening white band corresponding to the 'denuded' grey-white sulcus scleral appears (black arrows).

520

Pettitioner - New World Medical
Ex. 1013, p. 2 of 12

Jacobi 2000, p. 2 of 12

meshwork.⁶ From light microscopy of histological sections it is evident that, in addition to the peeling of the trabecular meshwork, gonioscurettage also causes damage to intracanalicular septa and the endothelium of the external wall of Schlemm's canal, and in some instances a disruption along the posterior wall of Schlemm's canal. Flaps of uveal tissue, capable of

Gonioscurettage

The underlying concept of gonioscurettage is to remove rather than incise or disrupt pathologically altered trabecular meshwork and to open a route for aqueous humour to egress either into Schlemm's canal or, where the external wall of the canal is damaged, to ooze out through microsplittings in the posterior scleral wall.⁶ The procedure is conceptually similar to goniotomy, except that trabecular tissue is scraped away from the scleral sulcus using an instrument similar to a microchhalazion curette (Fig. 1). The gonioscraper consists of a small handle and a slightly convex arm for intraocular use and closely resembles a cyclodialysis spatula. However, the tip of the instrument is shaped like a miniature bowl, 300 µm in diameter, with sharpened edges. To abrade clockwise and counter-clockwise, the scoop is vertically angled at 90° to either side.

Gonioscurettage is usually performed under direct visualisation of the anterior chamber angle through an optical gonioscopy lens. The gonioscopic lens, sclerostatic, the gonioscopic lens is directed against the scleral side. The scraper is hours to either side of the scleral angle. Great care is taken to ensure that the meshwork not to





Fig. 2. Ab interno gonioscurettage is performed with the aid of an operating microscope under gonioscopic observation.

traumatise adjacent intraocular structures, such as the corneal endothelium or the base of the iris. Intraoperatively, ragged strings of trabecular tissue can be seen to be removed by goniosabration, leaving an irregular pattern of a glistening white band corresponding to the denuded grey-white scleral sulcus (Fig. 3). At the end of the procedure, viscoelastic along with abraded trabecular debris is removed by means of irrigation-aspiration.

Morphological analysis of the treatment zones in human donor eyes clearly indicated the potential efficacy of gonioscurettage for completely removing the trabecular meshwork.⁶ From light microscopy of histological sections it is evident that, in addition to the peeling of the trabecular meshwork, gonioscurettage also causes damage to intracanalicular septa and the endothelium of the external wall of Schlemm's canal, and in some instances a disruption along the posterior wall of Schlemm's canal. Flaps of uveal tissue, capable of returning to their predissection position, were not observed in the specimens. Scanning electron microscopy shows that the trabecular meshwork is pulled away from its attachments, leaving ragged structures of Schlemm's canal within the scleral sulcus exposing bare sclera (Fig. 4).



The external diameter of the gonioscraper. (b) The intracanalicular arm of the gonioscraper.

Fig. 3. After goniosabration, an irregular pattern of a glistening white band corresponding to the 'denuded' grey-white scleral sulcus appears (black arrows).

Pettitioner - New World Medical
Ex. 1013, p. 2 of 12

Jacobi 2000, p. 2 of 12

observed in the specimens. Scanning electron microscopy shows that the trabecular meshwork is pulled away from its attachments, leaving ragged structures of Schlemm's canal within the scleral sulcus exposing bare sclera (Fig. 4).

Gonioscurettage

The underlying concept of gonioscurettage is to remove rather than incise or disrupt pathologically altered trabecular meshwork and to open a route for aqueous humour to egress either into Schlemm's canal or, where the external wall of the canal is damaged, to ooze out through microsplittings in the posterior scleral wall.⁶ The procedure is conceptually similar to goniotomy, except that trabecular tissue is scraped away from the scleral sulcus using an instrument similar to a microchhalazion curette (Fig. 1). The gonioscraper consists of a small handle and a slightly convex arm for intraocular use and closely resembles a cyclodialysis spatula. However, the tip of the instrument is shaped like a miniature bowl, 300 µm in diameter, with sharpened edges. To abrade clockwise and counter-clockwise, the scoop is vertically angled at 90° to either side.

Gonioscurettage is usually performed under direct visualisation of the anterior chamber angle through an operating microscope and a surgical gonioscopy lens (Fig. 2). Following injection of viscoelastic, the gonioscraper is inserted into the anterior chamber through a clear corneal incision and directed against the trabecular meshwork on the opposite side. The scraper is lightly passed over 2 to 3 clock-hours to either side of the nasal circumference of the chamber angle. Great care is taken while peeling off the uveal meshwork not to




Fig. 2. Ab interno gonioscurettage is performed with the aid of an operating microscope under gonioscopic observation.

traumatise adjacent intraocular structures, such as the corneal endothelium or the base of the iris. Intraoperatively, ragged strings of trabecular tissue can be seen to be removed by goniosabration, leaving an irregular pattern of a glistening white band corresponding to the denuded grey-white scleral sulcus (Fig. 3). At the end of the procedure, viscoelastic along with abraded trabecular debris is removed by means of irrigation-aspiration.

Morphological analysis of the treatment zones in human donor eyes clearly indicated the potential efficacy of gonioscurettage for completely removing the trabecular meshwork.⁷ From light microscopy of histological sections it is evident that, in addition to the peeling of the trabecular meshwork, gonioscurettage also causes damage to intracanalicular septa and the endothelium of the external wall of Schlemm's canal, and in some instances a disruption along the posterior wall of Schlemm's canal. Flaps of uveal tissue, capable of returning to their predissection position, were not observed in the specimens. Scanning electron microscopy shows that the trabecular meshwork is pulled away from its attachments, leaving ragged structures of Schlemm's canal within the scleral sulcus exposing bare sclera (Fig. 4).





Fig. 3. After goniosabration, an irregular pattern of a glistening white band corresponding to the 'denuded' grey-white scleral sulcus appears (black arrows).

The external diameter of the med. (b) The intracanalicular arm of recent damage to the iris-lens


Pettioner - New World Medical
Ex. 1013, p. 2 of 12

Jacobi 2000, p. 3 of 12



others.^{7,8} In these earlier studies, the trabecular meshwork was either excised using a trabeculectome⁷ or scraped away with the flat side of a goniotomy blade.⁸

Ex. 1018 (Ferrari)



Ferrari, p. 4 of 5

We found that the histological effects of AITC were different from with the classical goniotomy and trabeculotomy procedures (25). These latter produce a deep incision in the trabecular tissue with close edges of the wound. The histological picture after AITC also differs from goniotomy. In this procedure trabecular removal is associated with damage to the posterior wall of Schlemm's canal and collector vessels (13).

Ab-in-terno trabeculo-canalectomy: surgical approach and histological examination

our original idea of peeling away the TM alone actually removed both the TM and the inner wall of Schlemm's canal. This unexpected result might possibly achieve a better outflow than TM removal alone. Considering that the site of major resistance to the outflow of aqueous humor is at the juxtacanalicular portion of the TM and the inner wall of Schlemm's canal and that often, during non-penetrating filtering surgery better aqueous percolation is achieved by peeling the inner wall of the canal (27, 28), we suggest that removal of both the TM and the inner wall of Schlemm's canal would ensure better outflow than removal of the TM alone. However, with non-penetrating filtering surgery outflow can also be improved by an *ab externo* approach, leaving the TM intact (27-30).

We found that the histological effects of AITC were different from with the classical goniotomy and trabeculotomy procedures (25). These latter produce a deep incision in the trabecular tissue with close edges of the wound. The histological picture after AITC also differs from goniotomy. In this procedure trabecular removal is associated with damage to the posterior wall of Schlemm's canal and collector vessels (13).

Although our histological findings on cadaver eyes are encouraging problems may be encountered in clinical application of AITC. The fine details of anterior chamber angle structures cannot be clearly visualized in every case: corneal opacities, corneal edema

or the presence of blood in the anterior chamber may render gonioscopic observation inadequate. Like other *ab-interno* procedures, other pre-requisites for AITC are a stable anterior chamber and wide irido-corneal angle. Although viscoelastics can be used to stabilize the anterior chamber, sufficient widening of the irido-corneal angle cannot be achieved in every case. Predictable risks with AITC are: lens or corneal endothelium contacts, bleeding from the trabecular vessels and/or from Schlemm's canal, early intraocular pressure rise due to retention of viscoelastics, iris root damage, inadvertent cyclodialysis, bulbar hypotony.

ACKNOWLEDGEMENTS

The authors thank the Veneto Eye Bank Foundation for their kind co-operation.
Supported by funds from the Department of Surgical Sciences, University of Udine.

Reprint requests to:
Ettore Ferrari, MD
Department of Ophthalmology
University of Udine
Viale Venezia 410
33100 Udine
ettore.ferrari@ddsc.uniud.it

REFERENCES

1. Barkan O. A new operation for chronic glaucoma. Restoration of physiological function by opening Schlemm's canal under direct magnified vision. *Am J Ophthalmol* 1936; 19: 951-66.
2. Bunian HM. A case of Marfan's syndrome with bilateral glaucoma. A description of a new type of operation for developmental glaucoma (trabeculotomy *ab externo*). *Am J Ophthalmol* 1960; 50: 1187-95.
3. Smith R. A new technique for opening the canal of Schlemm. Preliminary report. *Br J Ophthalmol* 1960; 44: 370-5.
4. Nesterov AP, Batmanov YE. Study on morphology and function of drainage area of the eye of a man. *Acta Ophthalmol* 1972; 50: 337-41.
5. Nesterov AP, Batmanov YE. Trabecular wall of Schlemm's canal in the early stage of primary open-angle glaucoma. *Am J Ophthalmol* 1974; 78: 633-47.
6. Murphy CG, Johnson M, Alvarado JA. Juxtacanalicular tissue in pigmentary and primary open angle glaucoma: the hydrodynamic role of pigment and other constituents. *Arch Ophthalmol* 1982; 110: 1779-85.
7. Lütjens-Drecoll E, Shimizu T, Rohrbach M, Rohlen JW. Quantitative analysis of "plaque material" in the inner and outer wall of Schlemm's canal in normal and glaucomatous eyes. *Exp Eye Res* 1986; 42: 443-455.
8. Bleth GB, Quaranta CA. Indications for and results of iridocorneal angle incision (goniotomy, goniotrabeculotomy or trabeculotomy). *Trans Ophthalm Soc New Zealand* 1968; 20(suppl): S20-42.
9. Melamed S, Pei J, Puliatto CA, Epstein DL. Q-switched neodymium YAG laser trabeculopuncture in monkeys.

404

Petitioner - New World Medical
Ex. 1018, p. 4 of 5

Ex. 2021 (May 27, 2021 Netland Deposition Transcript)

1	2
1 UNITED STATES PATENT AND TRADEMARK OFFICE	1 UNITED STATES PATENT AND TRADEMARK OFFICE
2 BEFORE THE PATENT TRIAL AND APPEAL BOARD	2 BEFORE THE PATENT TRIAL AND APPEAL BOARD
3 <u>NEW WORLD MEDICAL, INC.,</u>	3 <u>NEW WORLD MEDICAL, INC.,</u>
4 Petitioner,	4 Petitioner,
5 -vs- Case IPR2020-01711	5 -vs- Case IPR2021-00065
6 U.S. Patent No. 9,358,155	6 U.S. Patent No. 10,123,905
7 MICROSURGICAL TECHNOLOGY, INC.,	7 MICROSURGICAL TECHNOLOGY, INC.,
8 Patent Owner.	8 Patent Owner.
9 <u>NEW WORLD MEDICAL, INC.,</u>	9 <u>NEW WORLD MEDICAL, INC.,</u>
10 Petitioner,	10 Petitioner,
11 -vs- Case IPR2021-00017	11 -vs- Case IPR2020-01573
12 U.S. Patent No. 9,820,885	12 U.S. Patent No. 9,107,729
13 MICROSURGICAL TECHNOLOGY, INC.,	13 MICROSURGICAL TECHNOLOGY, INC.,
14 Patent Owner.	14 Patent Owner.
15 <u>NEW WORLD MEDICAL, INC.,</u>	15 <u>NEW WORLD MEDICAL, INC.,</u>
16 Petitioner,	16 Petitioner,
17 -vs- Case IPR2021-00066	17 -vs- Case IPR2020-01573
18 U.S. Patent No. 9,999,544	18 U.S. Patent No. 9,107,729
19 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,	19 MICROSURGICAL TECHNOLOGY, INC.,
20 Patent Owner .	20 Patent Owner.
21 <u>VIDEOTAPED DEPOSITION OF PETER NETLAND, M.D., Ph.D.</u>	21 <u>VIDEOTAPED DEPOSITION OF PETER NETLAND, M.D., Ph.D.</u>
22 9:14 a.m. to 4:24 p.m.	22 9:14 a.m. to 4:24 p.m.
	23 May 27, 2021
	24 Charlottesville, Virginia
	25 Job No. 45352/4590692
	26 REPORTED BY: Rhonda D. Tuck, RPR, CRR
	27

Ex. 2021 92:14-22

Q. Do you recall testifying that surgical procedures for treating glaucoma can be classified as either ab-interno or ab-externo?

A. Yes.

Q. Must a surgical procedure for treating glaucoma be one or the other only?

A. No. I suppose they -- I don't think it does necessarily. I suppose there can be combinations of both of those.

92

1 A. I believe it is.
2 Q. What does the term "gonioretting" mean to
3 you?
4 A. So a gonioretting would imply to me an
5 operation of the angle that involves remove of tissue,
6 likely removal of tissue. It can just be a scraping,
7 but it's the scraping-type of procedure and possibly
8 cutting as well, but removal of tissue through a sort
9 of scraping/cutting process.
10 Q. And you believe your understanding of this
11 term as you've just defined it is commonly shared by
12 others in ophthalmology?
13 A. I believe so.
14 Q. Do you recall testifying that surgical
15 procedures for treating glaucoma can be classified as
16 either ab-interno or ab-externo?
17 A. Yes.
18 Q. Must a surgical procedure for treating
19 glaucoma be one or the other only?
20 A. No. I suppose they -- I don't think it
21 does necessarily. I suppose there can be combinations
22 of both of those.

93

1 Q. So it's not an absolutely binary
2 classification?
3 A. Right. There may be procedures that
4 combine those elements, ab-interno and ab-externo.
5 Q. And can you explain what you're thinking
6 about that might be an example of that?
7 A. Right. So I guess I'm saying that the
8 terms themselves don't exclude the possibility.
9 Generally speaking and probably for purposes of this
10 process the ab-interno would be an approach from the
11 inside of the eye to perform the procedure of treating
12 the angle, whereas an ab-externo would be from the
13 outside of the eye. Again, the terms may not exclude
14 those two things occurring during in the same
15 procedure, but most of the procedures that I'm
16 thinking of when I'm using those terms are one or the
17 other.
18 Q. So you've testified that the ordinary and
19 customary meaning of ab-interno to a person of
20 ordinary skill in the art, or a POSA, is to generally
21 mean from the inside?
22 MR. DEIGHAN: Objection, form.

Ex. 2021 124:17-21

Q. But the '729 Patent says the sides of its device are sharp and intended to cut tissue. Where does Quintana say that the sides of the Quintana device are sharpened to cut tissue?

A. Quintana does not specify that.

124

1 standard hypodermic needle tip that has two cutting
2 blades?

3 A. Yes.

4 Q. And you know that they are cutting blades
5 how?

6 A. Well, we can go to the declaration, but
7 just from -- and the declaration kind of goes through
8 the whole thing, I don't want to contradict that.
9 That would be the primary source for this information,
10 but the blades are similar to the '729 Patent. The
11 blades are at a location that becomes relevant as the
12 instrument is used. So in this case, as it's being
13 passed forward through the trabecular meshwork, the
14 edges that are relevant here would be on the sides,
15 the dual blades on the side of the single beveled
16 edge.

17 Q. But the '729 Patent says the sides of its
18 device are sharp and intended to cut tissue. Where
19 does Quintana say that the sides of the Quintana
20 device are sharpened to cut tissue?

21 A. Quintana does not specify that.

22 Q. And so your conclusion that Quintana does

Ex. 2021 131:16-19

Q. So is it your testimony that a cystotome is the same as a standard hypodermic needle that's bent at the tip?

A. Yes. In common usage, yes. There are

131

1 A. By bending it, bending the tip. So the
2 common usage would have been that needle holders were
3 used just as Quintana described. Every
4 ophthalmologist would have been familiar with this.
And then using a needle holder, which is a little bit
stronger, to bend the tip in a way that's
controllable.

So Murray Johnstone used standard lens
cystotomes which would have had a bent tip just
created by the surgeon, and, you know, much like the
design shown here in Patent '729, the tip was bent at
various places at the distal end of the needle up to
and including in the bevel, and the tip was bent using
that instrument, and he used that approach which was
in common usage at that time.

16 Q. So is it your testimony that a cystotome is
17 the same as a standard hypodermic needle that's bent
18 at the tip?

19 A. Yes. In common usage, yes. There are
20 commercially available products now, most of us use
21 those. We don't take the time to bend them ourselves.
22 But at that time it was commonly done by the surgeon

IPR2020-01573 Paper 29 at 35, 37, 54; 2020-01711 Paper 17 at 40-42, 50; 2021-00017 Paper 17 at 31.

Ex. 2021 262:3-6

Q. But you don't show the sides that you label here as needle cutting edges in the trabecular meshwork. Would you agree with that?

A. Correct. But it's a continuous -- it's an

262

1 meshwork?
2 A. Correct.
3 Q. But you don't show the sides that you label
4 here as needle cutting edges in the trabecular
5 meshwork. Would you agree with that?
6 A. Correct. But it's a continuous -- it's an
7 edge. There's a bit of an arc to it. But elsewhere
8 in this figure, clearly they've got it
9 a little bit back from the widest point, but I
10 point out for purposes of this deposition
11 now, the widest point might be the most
12 point to label. Although, this is correctly
13 my view.
14 Following up on that, if you look at the
15 point of separation in this depiction, that's
16 trabecular meshwork, is it?

263

1 A. Correct, as depicted here. The tissue can
2 stretch, so when it reaches the widest point, I mean,
3 maybe it's a little bit past it, maybe it's a little
4 bit before it when it starts cutting, when it's off
5 center a little bit, you know, one edge cuts a little
6 more than the other edge initially, you know, exactly
7 where it cuts relative to the widest point can vary a
8 little bit in real life. But the widest point is a
9 good thing to measure, as you're pointing out, because
10 that would be the maximal width of the strip that
11 would be removed.
12 MR. SUNG: Let's go off the record.
13 THE VIDEOGRAPHER: Okay. The time is
14 approximately 4:24 p.m., and we are off the
15 record.
16 (Break in proceedings.)
17 (Deposition adjourned at 4:24 p.m.)
18 * * * * *
19
20
21
22



Ex. 2021 262:20-263:11

Q. Following up on that, if you look at the widest point of separation in this depiction, that's not in the trabecular meshwork, is it?

A. Correct, as depicted here. The tissue can stretch, so when it reaches the widest point, I mean, maybe it's a little bit past it, maybe it's a little bit before it when it starts cutting, when it's off center a little bit, you know, one edge cuts a little more than the other edge initially, you know, exactly where it cuts relative to the widest point can vary a little bit in real life. But the widest point is a good thing to measure, as you're pointing out, because that would be the maximal width of the strip that would be removed.

262

1 meshwork?
2 A. Correct.
3 Q. But you don't show the sides that you label
4 here as needle cutting edges in the trabecular
5 meshwork. Would you agree with that?
6 A. Correct. But it's a continuous meshwork
7 edge. There's a bit of an overlap there
8 in the declaration that the -- you know, the
9 knowledge of the actual dual blade can be
10 towards the tip and further back as
11 clearly the widest point is, proximal, most
12 relevant.
13 In this figure, clearly they've got it
14 labeled a little bit back from the widest point, but I
15 would just point out for purposes of this deposition
16 that, you know, the widest point might be the most
17 relevant point to label. Although, this is correctly
18 labeled in my view.
19 Q. Following up on that, if you look at the
20 widest point of separation in this depiction, that's
21 not in the trabecular meshwork, is it?
22

263

1 A. Correct, as depicted here. The tissue can
2 stretch, so when it reaches the widest point, I mean,
3 maybe it's a little bit past it, maybe it's a little
4 bit before it when it starts cutting, when it's off
5 center a little bit, you know, one edge cuts a little
6 more than the other edge initially, you know, exactly
7 where it cuts relative to the widest point can vary a
8 little bit in real life. But the widest point is a
9 good thing to measure, as you're pointing out, because
10 that would be the maximal width of the strip that
11 would be removed.
12 MR. SUNG: Let's go off the record.
13 THE VIDEOGRAPHER: Okay. The time is
14 approximately 4:24 p.m., and we are off the
15 record.
16 (Break in proceedings.)
17 (Deposition adjourned at 4:24 p.m.)
18 * * * * *
19
20
21
22

IPR2020-01573 Paper 29 at 25-27; 2020-01711 Paper 17 at 26-27; 2021-00017 Paper 17 at 24-25; 2021-00065 Paper 18 at 21-22; 2021-00066, Paper 17 at 28-29.



Ex. 2022 (May 28, 2021 Netland Deposition Transcript)

265		266	
1	UNITED STATES PATENT AND TRADEMARK OFFICE	1	UNITED STATES PATENT AND TRADEMARK OFFICE
2	BEFORE THE PATENT TRIAL AND APPEAL BOARD	2	BEFORE THE PATENT TRIAL AND APPEAL BOARD
3	<hr/> NEW WORLD MEDICAL, INC.,	3	<hr/> NEW WORLD MEDICAL, INC.,
4	Petitioner,	4	Petitioner,
5	Case IPR2020-01711	5	Case IPR2021-00065
5	-vs- U.S. Patent No. 9,358,155	5	-vs- U.S. Patent No. 10,123,905
6	MICROSURGICAL TECHNOLOGY, INC.,	6	MICROSURGICAL TECHNOLOGY, INC.,
7	Patent Owner.	7	Patent Owner.
8	<hr/> NEW WORLD MEDICAL, INC.,	8	<hr/> NEW WORLD MEDICAL, INC.,
9	Petitioner,	9	Petitioner,
10	Case IPR2021-00017	10	Case IPR2020-01573
10	-vs- U.S. Patent No. 9,820,885	10	-vs- U.S. Patent No. 9,107,729
11	MICROSURGICAL TECHNOLOGY, INC.,	11	MICROSURGICAL TECHNOLOGY, INC.,
12	Patent Owner.	12	Patent Owner.
13	<hr/> NEW WORLD MEDICAL, INC.,	13	<hr/>
14	Petitioner,	14	
15	Case IPR2021-00066	15	VIDEOTAPED DEPOSITION OF PETER NETLAND, M.D., Ph.D.
15	-vs- U.S. Patent No. 9,999,544	15	9:07 a.m. to 10:37 a.m.
16	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,	16	May 28, 2021
17	Patent Owner.	17	Charlottesville, Virginia
18	<hr/>	18	
19	VIDEOTAPED DEPOSITION OF PETER NETLAND, M.D., Ph.D.	19	
20	9:07 a.m. to 10:37 a.m.	20	
21	May 28, 2021	21	Job No. 45353/4590726
21	Charlottesville, Virginia	22	REPORTED BY: Rhonda D. Tuck, RPR, CRR
22	Job No. 45353/4590726		
22	REPORTED BY: Rhonda D. Tuck, RPR, CRR		



Ex. 2022 285:4-8

Q. Would you agree that the intended purpose of a standard hypodermic needle is not to create a strip of tissue?

A. I would agree that the standard use is not to excise strips of tissue for a hypodermic needle .

285

1 tissue?

2 A. Yes, I would agree that that is the

3 standard use.

4 Q. Would you agree that the intended purpose

of a standard hypodermic needle is not to create a

strip of tissue?

7 A. I would agree that the standard use is not

8 to excise strips of tissue for a hypodermic needle .

9 Q. You testified that you recall addressing

10 the issue about sharpness and bluntness somewhere in

11 your declaration. Do you remember that?

12 A. Yes, I do remember discussing that.

13 Q. But then I had disagreed with you yesterday

14 about it, but I think that I can help clarify this.

15 A. Okay.

16 Q. You did not address sharpness and bluntness

17 in the declaration you made for IPR2020-01573

18 regarding the '729 Patent, but you did address

19 sharpness and bluntness in the declaration you made

20 for IPR2020-01711 regarding the '155 Patent. Would

21 you agree with that?

22 A. I'll have to just check the --

IPR2020-01573 Paper 29 at 10; 2020-01711 Paper 17 at 11; 2021-00017 Paper 17 at 8;
2021-00065 Paper 18 at 7; 2021-00066, Paper 17 at 8.



Ex. 2022 297:16-20

Q. Does Quintana provide any quantitative metrics to indicate that the beveled sides of the Quintana device tip are sharp enough to cut trabecular meshwork?

A. No. He made observations that he felt

297

1 Q. Describe what literature you read and
2 interpreted.

3 A. Well, in Quintana itself, he does assert
4 many times, and I believe there is evidence for that
5 in the manuscript, that he does remove strips of
6 tissue and sections, quote/unquote of tissue, and so
7 that's the relevant material that would be linked to
8 this discussion.

9 Q. But I'm asking whether --

10 A. These claims.

11 Q. But I'm asking whether you conducted any
12 studies to determine based on quantitative metrics
13 whether the beveled sides are sharp enough to cut
14 trabecular meshwork.

15 A. No.

16 Q. Does Quintana provide any quantitative
17 metrics to indicate that the beveled sides of the
18 Quintana device tip are sharp enough to cut trabecular
19 meshwork?

20 A. No. He made observations that he felt
21 indicated that it was cutting or removing strips, but
22 he didn't provide specific evidence of that, any

Ex. 2022 298:20-299:1

Q. But Jacobi does not provide any quantitative metrics to indicate whether the edge of the Jacobi gonioscraper is sharp enough to cut trabecular meshwork, does it?

A. To my recollection, you are correct.

298

measurements of that.

2 Q. At any time during the process of your
3 preparation of your declarations, as well as your
4 preparation for your testimony today, were you
5 informed that the beveled sides of the Quintana device
6 tip are sharp enough to cut trabecular meshwork by
7 quantitative metrics?
8 A. No.
9 Q. Dr. Netland, you've testified that in your
10 opinion, the edges of the Jacobi gonioscraper are
11 sharp enough to cut trabecular meshwork, correct?
12 A. Yes.
13 Q. Did you conduct any studies to determine
14 based on quantitative metrics whether the edges of the
15 Jacobi gonioscraper are sharp enough to cut trabecular
16 meshwork?
17 A. No. I reviewed the information in the
18 manuscripts, which provided suggestive evidence that
19 they are sharp enough to cut.
20 Q. But Jacobi does not provide any
21 quantitative metrics to indicate whether the edge of
22 the Jacobi gonioscraper is sharp enough to cut

299

1 trabecular meshwork, does it?
2 A. To my recollection, you are correct.
3 Q. And at any time during the process of your
4 preparation of your declarations as well as your
5 preparation for your testimony today, were you
6 informed that the edge of the Jacobi gonioscraper is
7 sharp enough to cut trabecular meshwork by
8 quantitative metrics?
9 A. No. By quantitative metrics, no. You are
10 correct.
11 Q. Apologies in advance. We always have to be
12 complete.
13 You've testified that in your opinion the
14 edges of the Lee device are sharp enough to cut
15 trabecular meshwork, correct?
16 A. Yes.
17 Q. Lee does not provide any quantitative
18 metrics to indicate that the edges are sharp enough to
19 cut trabecular meshwork; is that correct?
20 A. No, I haven't done a detailed search on the
21 information associated with this patent, but I agree
22 with you. It's not in the summary of the patent.

IPR2020-01573 Paper 29 at 45-49; 2020-01711 Paper 17 at 51-54; 2021-00017 Paper 17 at 35-38;
2021-00065 Paper 18 at 32-36; 2021-00066, Paper 17 at 43-47.

Ex. 2022 299:17-22

Q. Lee does not provide any quantitative metrics to indicate that the edges are sharp enough to cut trabecular meshwork; is that correct?

A. No, I haven't done a detailed search on the information associated with this patent, but I agree with you. It's not in the summary of the patent.

1 measurements of that.

298

2 Q. At any time during the process of your
3 preparations, as well as your
4 preparation today, were you
5 of the Quintana device
6 informed that the edge of the Jacobi gonioscraper is
7 sharp enough to cut trabecular meshwork by
8 quantitative metrics?

9 testified that in your
10 opinion, the edges are

11 by studies to determine
12 whether the edges of the
13 device are sharp enough to cut trabecular

14 the information in the
15 suggestive evidence that

16 it.
17 I did not provide any
18 information as to whether the edge of
19 the device is sharp enough to cut

299

1 trabecular meshwork, does it?

2 A. To my recollection, you are correct.

3 Q. And at any time during the process of your
4 preparation of your declarations as well as your
5 preparation for your testimony today, were you
6 informed that the edge of the Jacobi gonioscraper is
7 sharp enough to cut trabecular meshwork by
8 quantitative metrics?

9 A. No. By quantitative metrics, no. You are
10 correct.

11 Q. Apologies in advance. We always have to be
12 complete.

13 You've testified that in your opinion the
14 edges of the Lee device are sharp enough to cut
15 trabecular meshwork, correct?

16 A. Yes.

17 Q. Lee does not provide any quantitative
18 metrics to indicate that the edges are sharp enough to
19 cut trabecular meshwork; is that correct?

20 A. No, I haven't done a detailed search on the
21 information associated with this patent, but I agree
22 with you. It's not in the summary of the patent.